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ABSTRACT  
 Damage to vascular cells of the aorta drives vascular dysfunction and disease. 
Nicotinamide adenine dinucleotide (NAD+) is a cellular metabolite critical to cellular 
health, but NAD+ levels decline during oxidative insults and aging. The NAD+ precursor, 
nicotinamide riboside (NR) can augment NAD+ levels. Herein, I determined whether 
orally administrated NR could protect the aorta of middle-aged mice from acute (3-day) 
and sustained (28-day) angiotensin II (Ang II) infusion-induced damage. I demonstrate, 
for the first time, that Ang II infusion can induce early death of aortic endothelial cells 
and smooth muscle cells, that this early death response was associated with DNA strand 
breakage, and that NR abrogated both cell death and DNA degradation. In addition, NR 
blunted DNA oxidation, proinflammatory signaling, and vascular cell senescence, during 
sustained delivery of Ang II. Thus, orally administered NR can protect the aorta from 
damage imposed by Ang II, a finding with clinical implications.  
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1  INTRODUCTION 
This introduction will begin by briefly introducing cardiovascular disease, the 
aorta and its cellular composition. Nicotinamide adenine dinucleotide (NAD+) may 
promote vascular cell health and its biosynthesis and various cellular roles will be 
introduced. Subsequently, proteins that consume NAD+ will be comprehensively 
reviewed, highlighting their roles in NAD+ homeostasis, cellular health and pathology. I 
will then discuss the decline in NAD+ seen during oxidative stress and aging. 
Furthermore, nicotinamide riboside (NR) supplementation will be introduced as a means 
to counteract this decline. Finally, angiotensin II (Ang II) infusion will be introduced as a 
model of age/pathology-related vascular oxidative stress, and the potential for this to 
benefited by NR administration will be introduced. 
 
1.1  Cardiovascular disease, the aorta and its cellular constituents    
Cardiovascular disease remains the commonest cause of death globally1. Critical 
to cardiovascular health is the maintenance of blood vessel structure and function. The 
aorta is the largest vessel in the body, responsible for the distribution of blood to the 
downstream systemic circulation2. Due to its proximity to the heart, the aorta is exposed 
to unique biophysical stresses and is susceptible to aneurysms, atherosclerosis and 
stiffening3,4. Dysfunction in cells that comprise the aorta has been implicated in these 
conditions 5,6. 
The aorta is lined by a  single layer of endothelial cells (ECs), which together with 
underlying extra cellular matrix (ECM) and scattered cells, constitutes the tunica intima7. 
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These endothelial cells control the permeability of the vessel wall, secrete 
vasculoprotective compounds, and crosstalk with vascular smooth muscle cells (VSMCs) 
to alter vessel dynamics7.VSMCs are found in the tunica media. This is the thickest 
region of the aortic wall, which is also made of ECM including distinct layers of elastin. 
VSMCs contract and relax to alter blood flow, response to vessel injury and secrete ECM 
during development and disease. The outermost layer of the aorta is the tunica adventitia. 
This layer is comprised of loose connective tissue and a number of cell types including 
fibroblasts and progenitor cells8. The adventitia anchors vessels to organs and plays a role 
in tissue repair and inflammation8.  
Damage to ECs and VSMCs within the aortic wall compromises their function 
and is considered a driver of vascular disease5,6.  Biophysically, aortic cell damage can 
entail the breakage of DNA strands and the fragmentation of DNA as part of the cell 
death cascade.9,10. DNA damage can be induced by oxidative stress which is considered a 
key feature of cardiovascular disease.11,12. Thus, strategies that allow ECs and VSMCs to 
resist damage, including oxidative damage and DNA degradation, may be critical to 
reducing aortic disease and its complications. One such strategy is the provision of a 
NAD+ precursor to augment the cellular levels of NAD+, a metabolite that promotes cell 
health and function, including resistance to oxidative stress13. I discuss this strategy in the 
following sections, introducing NAD+, its biosynthesis, cellular roles and homeostasis.  
 
 
 
 
		
3	
1.2  NAD+: Routes of synthesis and cellular functions 
1.2.1  NAD+: A brief history 
NAD+ (nicotinamide adenine dinucleotide) is necessary to sustain life and 
accordingly, so are it’s biosynthetic precursors. In the absence of adequate dietary NAD+ 
precursor intake, a condition termed Pellagra develops, which was epidemic in United 
States during the 20th Century14. Research determined that niacin, now known as a 
precursor to NAD+, could cure Pellagra. This eradicated the disease14. In parallel with 
this, NAD+ was	 identified	 and	 demonstrated	 to	 be	 involved	 in	 cellular	 redox	reactions15.	Hence,	NAD+	precursor	 intake	has	been	known	as	an	important	aspect	of	 human	 health	 and	 nutrition.	 However,	 in	 recent	 decades,	 NAD+	 has	 been	identified	 as	 a	 metabolite	 with	 several	 cellular	 functions;	 whose	 levels	 decline	during	 age	 and	 disease,	 impacting	 cellular	 health16.	 Thus,	 supplementation	 with	NAD+	precursors	has	been	begun	to	be	investigated	as	a	strategy	to	maintain	cellular	NAD+	levels	during	aging	and	disease16.				
1.2.2  NAD+ synthesis through dietary tryptophan  
Tryptophan (Trp) is an essential amino acid, with several biological roles beyond 
protein synthesis17. Trp is a precursor for serotonin and melatonin, but is primarily 
catabolized in the liver through the kynurenine (KYN) pathway, which can yield NAD+17. 
This occurs through an 8-step pathway, termed the de-novo pathway, because the 
nicotinamide base is made de novo and not recycled, as is the case in other NAD+ 
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synthetic pathways. These latter pathways are termed salvage pathways. Interestingly, 
Trp will only yield NAD+ if there is enough substrate to saturate the activity of enzymes 
directing kynurenine pathway intermediates through alternate routes18. For this reason, 
and because of the pleotropic biological functions of Trp, it is estimated that 60 mg of 
Trp is equivalent to only 1 mg of the NAD+ precursor niacin19. Therefore, Trp is not an 
ideal precursor to NAD+ and cannot sustain NAD+ requirements20. In addition, the KYN 
pathway should not be augmented as its intermediates can induce pathology21.   
 
1.2.3  NAD+ synthesis through dietary salvage pathway intermediates  
When NAD+ is consumed by cellular proteins, nicotinamide (NAM) is formed as 
a byproduct and can be recycled to NAD+ through several salvage pathway 
intermediates20. These intermediates, and NAD+ itself, are naturally present in whole 
food and can be obtained through the diet to generate intracellular NAD+ 22,23,24. Several 
early animal studies have shed light on the absorption of these precursors (Fig. 1).  
Studies suggest that NAD+ and most of its salvage precursors are converted to 
NAM in the small intestine before absorption25. In the small intestine, NAD+ is converted 
to NAM directly26 or indirectly25 through sequential conversion to nicotinamide 
mononucleotide (NMN), NR, and then NAM. This indirect pathway gives insight into the 
intestinal absorption of these NAD+ precursors (NMN, NR, NAM). NMN appears to be 
rapidly converted to NR, which accumulates and is subsequently converted to NAM25. 
NAM is then the major intestinal uptake product, and accordingly, when NAM itself is 
injected into the small intestine it is absorbed intact25. However, when NR is 
administered orally,  some is also directly absorbed and utilized to generate tissue 
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NAD+27. Nicotinic acid (NA) appears to be the only salvage intermediate not 
substantially absorbed as NAM. Instead, when injected in the small intestine, NA remains 
as is and is absorbed largely intact.  
Understanding the absorption of these precursors is important as they appear to 
elevate NAD+ and NAD+ breakdown products to different degrees28. This may be due to 
minor but relevant absorption of non-NAM/NA NAD+ precursors, as has been seen with 
NR27. As well as tissue-specific utilization of absorbed precursors27,29,28.  
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Figure 1.1 NAD+ precursor uptake and metabolism. 
This figure illustrates the absorption and metabolism of NAD+ precursors from the 
intestine to the inside of a cell. As precursors are absorbed from the intestinal lumen to 
the circulation, intestinal cells do perform some minor intracellular metabolism, which is 
not highlighted in this figure. Also not shown is intra- to extra-cellular precursor transport 
and transport from the circulation to the intestinal lumen. Dashed lines indicate less 
elucidated pathways, which may be due to intracellular precursor metabolism and 
secretion. The purple dashed line indicates a pathway that has been hypothesized but not 
directly proven. Abbreviations used are: NAD+, nicotinamide adenine dinucleotide; 
NMN, nicotinamide mononucleotide; NR, nicotinamide riboside; NAM, nicotinamide; 
NA, nicotinic acid; Trp, tryptophan; NAMN, nicotinic acid mononucleotide; NAAD, 
nicotinic acid adenine dinucleotide; NRK1/2, nicotinamide riboside kinase 1/2; NAMPT, 
nicotinamide phosphoribosyltransferase; NMNAT1/2/3, nicotinamide mononucleotide 
adenylyltransferase 1/2/3; NARPT, nicotinate phosphoribosyltransferase; NADSYN, 
NAD+ synthase. 
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1.2.4  NAD+ synthesis and salvage at the cellular level 
In this section, I will outline the handling and processing of NAD+ precursors, 
specifically, intracellular and extracellular transport and processing. NAM, NA and Trp 
can all be directly transported across the cell membrane for utilization30. Intracellularly, 
NAM requires the least processing, undergoing conversion to NMN by the rate-limiting 
enzyme nicotinamide phosphoribosyltransferase (NAMPT) and subsequent adenylation 
by nicotinamide mononucleotide adenylyltransferase (NMNAT1/2/3) to form NAD+20. 
NA on the other hand, goes through the 3-step Preiss-Handler pathway, from NA to 
nicotinic acid mononucleotide (NAMN) to nicotinic acid adenine dinucleotide (NAAD) 
and finally NAD+20. Interestingly, the Trp 8-step de-novo pathway, which also occurs 
intracellularly, converges with the 3-step Preiss-Hanlder pathway at NAAD (step 7)31. 
Not all precursors can cross the cell membrane, as is the case with NMN20. Extracellular 
NMN must first be converted to NR, which can then be transported across the cell 
membrane by nucleoside transporters29. NAD+ is also largely imported into the cell by 
conversion to NMN and subsequently NR20. Once across the cell membrane, 
nicotinamide riboside kinases (NRK1/2) convert NR back to NMN, which is 
subsequently converted to NAD+ by NMNAT1/2/320. Interestingly, NAMPT also exists 
extracellularly, where it can convert NAM to NMN32.  
Importantly, when NAD+ is utilized by sirtuins, poly (ADP-ribose) polymerases 
(PARPs) or NADases, it is cleaved to form NAM and ADP-ribose (Adenosine 
diphosphate ribose)20. This NAM can be salvaged back to NAD+ by NAMPT and 
NMNAT1/2/331. This salvage pathway is believed to be critically important for cellular 
NAD+ homeostasis as blood levels of NAD+ precursors are significantly lower than those 
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required to elevate NAD+ in vitro20. 
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Figure 1.2 NAD+ synthesis from NR and through the salvage pathway. 
This figure depicts the chemical structure of NAD+ and intermediates arising during NR- 
and salvage-derived NAD+ synthesis. Classically, NR is converted to NMN and 
subsequently NAD+. Recently however, it has been identified that NR can directly form 
NAAD, which can then be converted to NAD+. When NAD+ is consumed, NAM is 
formed as a byproduct. NAM can then be salvaged back to NAD+ through conversion to 
NMN and subsequently NAD+. Abbreviations used are: NAD+, nicotinamide adenine 
dinucleotide; NMN, nicotinamide mononucleotide; NR, nicotinamide riboside; NAM, 
nicotinamide; NAAD, nicotinic acid adenine dinucleotide; NRK1/2, nicotinamide 
riboside kinase 1/2; NAMPT, nicotinamide phosphoribosyltransferase; NMNAT1/2/3, 
nicotinamide mononucleotide adenylyltransferase 1/2/3; NADSYN, NAD+ synthase. 
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1.2.5  Importance of NAD+ in redox metabolism  
NAD+ is traditionally known for its role in cellular energy metabolism33. 
Cytoplasmic conversion of glucose to pyruvate in glycolysis requires NAD+. Specifically, 
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) reduces NAD+ to NADH 
(nicotinamide adenine dinucleotide hydride), converting the glycolytic intermediate 
glyceraldehyde 3-phosphate to 1-3-biphosphoglycerate. Cytosolic NAD+ can also be 
reduced to NADH during the formation of acetyl-CoA from pyruvate. The resulting 
NADH from these reactions can be converted back to NAD+ in the cytoplasm by the 
lactate forming action of lactate dehydrogenase. Cytosolic NADH can also be shuttled to 
the mitochondrion where another pool of NADH exists from the local reduction of NAD+ 
by several steps in the tricarboxylic acid cycle. In the mitochondria, Complex I of the 
electron transport chain (ETC) oxidizes NADH back to NAD+, gaining 2 electrons in the 
process. The gain and transfer of these electrons among ETC complexes facilitates the 
pumping of protons from the mitochondrial matrix to the intermembrane space, creating a 
proton gradient. Protons flowing down this gradient through ATP (adenosine 
triphosphate) synthase, power oxidative phosphorylation of ADP (adenosine 
diphosphate) to form ATP. Here in lies the importance of NAD+ in cell and organism 
viability as a key player in ATP generation.  
 
1.2.6  Importance of NAD+ in NADP+/NADPH homeostasis 
NADP+/NADPH (nicotinamide adenine dinucleotide phosphate/nicotinamide 
adenine dinucleotide phosphate hydride) are also derived from NAD+ and have distinct 
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cellular roles. Addition of a phosphate group to NAD+ by NAD+ kinase forms NADP+,  
which is rapidly dehydrogenated to NADPH34. Hence, NADPH is present in higher 
concentrations than NADP+ and both are maintained at much lower levels than cellular 
NAD+35. Reduction of NADPH to NADP+ is important for forming antioxidants, 
powering detoxifying enzymes and for NADPH oxidase activity31. It is also utilized for 
the synthesis of DNA, fatty acids, steroids and forming of the calcium mobilizer NAADP 
(nicotinic acid adenine dinucleotide phosphate)36. 
 
1.2.7  Importance of NAD+ as a co-substrate for proteins  
The previous sections highlighted NAD+’s role in energy metabolism. Here I will 
briefly introduce NAD+’s role as a co-substrate for enzymatic reactions mediated by 
cellular proteins. Each protein class and their functions will be more thoroughly reviewed 
in section 1.2.  
There are 3 classes of cellular proteins that consume NAD+ for their activity - 
sirtuins, PARPs and NADases. Sirtuins and PARPs are both important for cellular health, 
but PARP-1 has a lower Km and larger Vmax for NAD+ than sirtuins37. Thus, PARP-1 
activity is ordinarily not limited by NAD+ availability, but sirtuin activity is particularly 
sensitive37.  
This phenomenon becomes particularly important during conditions of oxidative 
stress that induce DNA damage and therefore activate PARP. PARP is a DNA damage 
repair protein, that cleaves NAD+, liberating the ADP-ribose (ADPR) moiety to place it 
at sites of DNA damage38. Importantly, this process creates chains of poly ADP-ribose 
(PAR) to recruit DNA damage repair protein. A consequence however, is that this can 
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deplete NAD+ levels39. Severe NAD+ depletion and PARP activation can impair ATP 
synthesis resulting in cell death35. Viable cells with reduced NAD+ levels will have less 
substrate for sirtuin activity, impacting its pleiotropic and important functions in cell 
health20. Furthermore, NAM is a byproduct of PARP mediated NAD+ consumption, and 
NAM itself can suppress sirtuin activity40. 
Sirtuins possess deacetylase activity and perform this function by breaking NAD+ 
into nicotinamide and ADPR, while placing the acetyl group from their target on the 
ADPR moiety, forming O-acetyl-ADPR41. Some sirtuins can also modify targets by their 
ability to desuccinlyate, demalonyate, deglutarylate, decrontolyate, lipomidate, and 
remove fatty acids20. Interestingly, SIRT1 can deacetylate PARP-1, suppressing its 
activity42. However, this action is suppressed during PARP-mediated NAD+ depletion, 
potentially increasing PARP activity and further lowering sirtuin activity37. 
The third class of NAD+-consuming proteins are NADases. Cluster of 
differentiation 38 (CD38) is the major known NADase. CD38 is a transmembrane protein 
that utilizes NAD+ to form cyclic ADP-ribose (cADPR). cADPR is a secondary 
messenger, regulating several biological functions through calcium signaling43. CD38 is 
constitutively active43 and is a major NAD+ consumer, with a lower Km for NAD+ than 
PARP-120. Furthermore, CD38 expression/activity can be increased by several stimuli 
including inflammatory cytokines44 and Ang II45. Inhibition of PARP46 or CD3847 
increases NAD+ levels and imparts protection in some models of disease by promoting 
sirtuin activity20.  
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1.3  NAD+ consumers and their role in resistance to oxidative stress and                          
aging  
 
1.3.1  Sirtuins, a critical protein family in preventing cardiovascular disease 
As previously visited, sirtuins possess deacetylase activity and act on many 
targets regulating cellular health. Seven different sirtuins exists, with distinct cellular 
localization and deacetylation targets. SIRT1 is primarily found in the nucleus but can 
also be moved to the cytoplasm48. SIRT2, on the other hand, is located exclusively in the 
cytoplasm. SIRT3-5 are confined to the mitochondria and SIRT6/7 are predominately 
found in the nucleus.  
Interest in sirtuins first grew from reports demonstrating their importance in 
enhancing yeast replicative lifespan49. Further studies demonstrated increased longevity 
when overexpressing sirtuins in nematodes50 and fruitflies51. Although some 
contradicting studies emerged, these results have now been independently replicated41. 
Meanwhile, many molecular targets of sirtuins have been studied and continue to be 
elucidated. Briefly, sirtuins act on pathways involved in cell survival, DNA damage 
repair, senescence, anti-oxidant defense, inflammation and many more52. Sirtuin 
deacetylase activity can impact these pathways by regulating transcription, activity and 
localization of proteins involved in these pathways53. Accordingly, knock out (KO) and 
overexpression of sirtuins has profound effects in many models of disease, including 
vascular diseases.  
In human abdominal aortic aneurysm (AAA) samples, SIRT1 expression and 
activity are reduced54. Furthermore, when aged mice are infused with Ang II, vascular 
smooth muscle cell (VSMC) SIRT1 KO decreases survival and increases AAA severity 
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and VSMC senescence54. Moreover, overexpression of SIRT1 in VSMCs has been 
reported to attenuate Ang II-induced hypertension, vascular remodeling and 
inflammation55. SIRT1 expression is also reduced in human atherosclerotic plaques. 
Inactivation of SIRT1 in VSMCs of high-fat-diet(HFD)-fed ApoE-/- mice leads to 
increased plaque area, DNA damage and apoptosis56. In mice fed a high-fat-high-sugar 
diet, VSMC SIRT1 KO inhibited overnight fasting-induced reductions in aortic 
stiffness57. Furthermore, SIRT1 overexpression/activation abrogated long term increases 
in aortic stiffness and ROS, while decreasing TNFα-induced aortic vascular cell adhesion 
molecule-1 (VCAM-1) expression. SIRT1 expression is also reduced by HFD and 
endothelial cell (EC) SIRT1 overexpression in ApoE-/- mice mitigates HFD-induced 
atherosclerotic lesions and reductions in endothelium-dependent vasodilation58. 
Accordingly, SIRT1 KO in high-cholesterol-fed ApoE-/- mice promotes atherosclerosis 
and associated inflammation59. SIRT6 KO also promotes atherosclerosis and impairs 
endothelium-dependent relaxation60. 
  
1.3.2  PARP-1 and its role in genomic integrity maintenance and cell death 
As previously discussed, the PARP family of proteins consume NAD+ to form 
ADP-ribose units on target proteins. PARP-1 is the most studied member of the PARP 
family and accounts for >90% of ADP-ribose synthesis61. However, 17 PARP protein 
family members exist, with distinct functions and subcellular localization. PARP-1 plays 
a role in both single62 and double strand break repair63,64. Following DNA damage, 
PARP-1 is activated, consuming NAD+ to create PAR chains at sites of DNA damage, on 
associated repair proteins, and even on itself65. This creates a docking site which is used 
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to recruit repair machinery and chromatin remodeling proteins to facilitate DNA repair65. 
PAR chains also promote phase separation at sites of damage, important for spatial 
organization of repair proteins by intracellular compartmentalization66. However, 
excessive PARP-1 activity and PARylation promotes cell death, possibly signaling DNA 
damage that is considered excessive/irreparable or by metabolic collapse.  
Several modes of cell death involve PAR/NAD+. Traditionally, Berger’s cell 
suicide hypothesis proposed that NAD+ consumption by PARP leads to ATP depletion, 
metabolic failure and necrotic death67. However, recent work has demonstrated that 
marked NAD+ decline, induced by inhibiting NAMPT, does not necessarily directly 
impact ATP levels or glycolysis68. Instead, PARP activation-derived PAR can bind to and 
inhibit the glycolytic enzyme hexokinase (and perhaps other Krebs cycle enzymes) 
leading to ATP depletion. Others have also implicated hexokinase and demonstrated that  
PARP activation-induced reductions in ATP occur before NAD+ decline69. Although not 
highlighted by the authors, eventual reductions in NAD+ were associated with further 
drops in ATP, suggesting both mechanism may be at play. 
Parthanatos is a form of regulated necrosis that is associated with PARP 
hyperactivity and NAD+/ATP depletion70. Exclusive to Parthantos is nuclear 
translocation of apoptosis-inducing factor (AIF) from the mitochondria, inducing large 
scale chromatinolysis and cell death70. Although this pathway hasn’t been fully 
elucidated, inhibition of the PAR clearance enzyme poly (ADP)-ribose glycohydrolase 
(PARG), leads to PARP activation-induced neuronal death without substantial NAD+ 
depletion (mild ~15% NAD+ decline)71. Furthermore, mutation of AIF’s PAR binding 
site prevented translocation to the nucleus and cell death following PARP-1 activation72. 
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Recent work has also demonstrated that PARG activity can promote AIF-mediated death, 
by liberating PAR, creating protein-free PAR chains, which can subsequently migrate to 
the mitochondria and interact with AIF73. Although other PAR clearance enzymes exist, 
PARG preferentially acts on protein-bound PAR and appears to create free-PAR small 
enough to traverse the nucleus73. Mitochondrial permeability transition (MPT) also 
appears to be important, as the MPT inhibitor cyclosporin A prevented AIF translocation 
and cell death74. NAD+ repletion after oxidative stress also prevented MPT and cell 
death. Furthermore, depletion of NAD+ with NADase induced AIF translocation and cell 
death, that was rescuable with pyruvate, even in PARP-1-/- neurons75. This suggests that 
NAD+ depletion does directly cause metabolic changes that mediate AIF translocation. 
Pyruvate also prevented MPT and cell death. Further complicating matters, AIF interacts 
with hexokinase and could therefore play a role in ATP decline76. PARP activation has 
also recently been demonstrated to influence mitochondrial ROS production through 
actions on activating transcription factor 4 (ATF4)77. ATF4 silencing prevented 
improvements in cell survival by PARP inhibition after oxidative stress, suggesting this is 
an important contributor to cell death.   
Necroptosis is another form of regulated necrosis and is mediated through 
receptor interacting protein kinases (RIPKs). Importantly, necroptosis appears to involve 
PARP. In TNF-related apoptosis inducing ligand (TRAIL)-induced necroptosis, PARP-1 
appears downstream of RIPK1 and 3, and their inhibition reduced PARP activation78. 
Inhibition of PARP also reduced the number of TRAIL-induced necrotic cells.  
PARP is generally considered to have little contribution to apoptosis79.  In fact, 
cleavage and therefore inactivation of PARP by caspases is one of the first steps in 
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apoptosis80. Furthermore, apoptosis requires ATP which is not necessarily abundant 
during PARP activation81. In line with this, a number of studies have demonstrated no 
effect of PARP on extrinsic and intrinsic apoptosis79. However, PAR may still be 
important during apoptotic death as it promotes the release of the inflammatory 
stimulator high mobility group box 1 (HMGB1) from damaged cells82.  PARylated 
HMGB1 binds to phosphatidylserine/RAGE (receptor for advanced glycation end 
products), impeding the clearance of apoptotic cells by the immune system83. A 
phenomenon that usually occurs before late-apoptotic cell membrane disruption, which 
triggers inflammation84.  
 
1.3.3  CD38, a NADase and major NAD+ consumer 
NADases are enzymes that hydrolyze NAD+, forming nicotinamide and ADPR. 
Other commonly used names for these enzymes include NAD+ glycohydrolases and 
NAD+ nucleosidases85. Cluster of differentiation 38 (CD38) is the major known NADase, 
a constitutively active, ubiquitous transmembrane protein with ecto-enzyme activity43. 
CD38 primarily functions as a type 2 plasma membrane protein, with extracellular 
NADase activity86. However, it has also been identified with its catalytic domain facing 
intracellularly87, as a soluble protein88, and within the nuclear membrane89. Its 
homologue, cluster of differentiation 157, has also been identified but less thoroughly 
investigated. CD38 uses NAD+ to form cADPR and nicotinamide and may also form 
NAADP from NADP+90. As most CD38 activity exists extracellularly, it has been 
proposed that intracellular NAD+ is transported extracellularly through connexin 43 
hemichannels and cleaved to form cADPR, which is internalized by CD38 or through 
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nucleoside transporters91. cADPR is a second messenger that regulates intracellular 
calcium release91. This impacts several biological functions, and importantly, plays a role 
in Ang II-induced NADPH oxidase-derived oxidative stress92,93. CD38 is very inefficient, 
requiring hydrolysis of ~100 NAD+ molecules to generate one cADPR94.  Accordingly, 
CD38 KO can markedly increase NAD+ levels, although with considerable variation 
between tissues and studies (2- to 27-fold95, 0- to 6-fold96, 0- to 2-fold97, 3.5-fold98). This 
likely has to do with tissue specific expression of CD38 which also varies largely (5- to 
24-fold)95. CD38 expression has been measured in several distinct rat arteries and can 
vary up to ~14-fold, with relatively low expression in the aorta99 All together, CD38 is a 
major NAD+ consumer and is considered to be an important regulator of NAD+ levels.   
 
1.4  NAD+ decline during oxidative stress and aging  
1.4.1  NAD+ decline during acute oxidative stress 
It has been well established that oxidative stress, in both an acute and chronic 
(e.g. age-related) manner, lowers the levels of intracellular NAD+. The classical paradigm 
is that ROS damages DNA, triggering the activation of PARP-1, which consumes NAD+ 
to initiate DNA repair79. ATP decline is a consequence of, or associated with, PARP 
activation-induced NAD+ decline, as discussed in depth in section 1.2.2. This can result 
in necrotic cell death due to metabolic collapse, or contribute to programmed modes of 
cell death38. Furthermore, a PARP-mediated decline in NAD+ lowers sirtuin activity, 
impacting cellular health37. This oxidative stress-induced decline in NAD+ has also been 
hypothesized to contribute to chronic age-related NAD+ decline100.  
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1.4.2  NAD+ decline during aging and disease 
Animal and emerging human data have demonstrated that there is a progressive 
NAD+ decline over the course of an organism’s lifespan. The reason for this decline 
appears to be multifaceted, with evidence of increased NAD+ consumption and decreased 
NAD+ synthesis. Recent work in mice demonstrated that mRNA/protein expression and 
activity of the NADase CD38, a major NAD+ consumer, increases in liver, adipose tissue, 
spleen and skeletal muscle with age97. Human adipose tissue was assayed and also 
exhibited increased CD38 mRNA with age. In the murine liver, where NMNAT mRNA 
was measured, a significant decline in NMNAT1 was observed along with nonsignificant 
drops in NMNAT2/3. CD38 upregulation in mice was associated with a fall in NAD+, 
with no change in the protein/mRNA expression of NAMPT and a decline in PARP-1 
protein expression. However, mice with CD38 KO did not have a decline in tissue NAD+ 
content when aged to 32 months. This work implicates NAD+ consumption by CD38 as 
the major cause of age-associated NAD+ decline, while deemphasizing PARP and 
NAMPT’s role. In contrast to this, another study reported age-related increases in PARP 
protein expression/activity in rat heart, liver, kidney and lung tissue, along with declining 
NAD+100. A decrease in anti-oxidant capacity, oxidation and DNA damage was observed 
in these tissues with age. This suggests that age-related oxidative stress/DNA damage 
may decrease NAD+ by increasing PARP activity. This study was repeated in the rat 
brain with identical results in the hippocampus, cortex, cerebellum and brainstem101. 
Here, NADase activity was also measured and significantly increased with age.  
Importantly, translational work has demonstrated an age-associated decrease in 
brain NAD+ in humans102. Furthermore, in human skin samples, age was negatively 
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correlated with NAD+ levels and positively correlated with oxidation, DNA damage, and 
PARP activity in males103. In a recent study, liver samples obtained from patients <45 
years old contained ~33% more NAD+ than samples from patients >60 years old104. 
These samples also revealed a reduction in NAMPT protein and an increase in NMNAT 
protein expression. This pattern was also displayed in livers of 4- vs. 12- vs. 20-month-
old mice. In the kidney of aged mice, NAMPT mRNA and NAD+ decline has been 
observed, along with a reduction in NMNAT1/3 mRNA105. Overall, animal data has 
revealed age-related reductions in NAD+ in the pancreases106, spleen97, liver100, brain107, 
heart100, kidney105, lung100, skeletal muscle106, muscle stem cells108, white adipose 
tissue106 and retina109. 
 In addition, reductions in NAD+ and related NAD+-producing enzymes have been 
observed in disease. Important to this project, we have demonstrated that NAMPT 
expression is reduced in dilated vs. non-dilated ascending aortas110. Also of interest is a 
decline in endothelial progenitor cell (EPC) NAD+/NAMPT seen in diabetic patients111. 
Here, blood EPC number correlated with NAD/NAMPT levels and was increased upon 
nicotinamide administration. Tissue NAD+ decline has also been observed during 
HFD106, ischemia112, diabetic retinopathy109, light-induced retinal degeneration109, noise-
induced hearing loss (n.s.)113, muscular dystrophy114 and environmental toxin 
exposure115. 
 
1.4.3  Supplemental NAD+ precursors: Advantage nicotinamide riboside 
A number of NAD+ precursors have been synthesized and administered in models 
of disease to augment NAD+ levels. However, the current evidence suggests that NR may 
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be one of the best NAD+ precursor in several respects. Orally administered NR elevates 
liver NAD+ similarly to orally delivered NAM, over the course of 12 hours (AUC: area 
under the curve)28. However, peak NAD+ was ~2-fold greater with NR compared to 
NAM. More importantly, levels of ADP-ribose, indicative of NAD+-consuming activity, 
were ~3-fold greater with NR, perhaps due to negative feedback of sirtuins by NAM. In 
line with this evidence, NAM was not as effective as NR in reversing muscle pathology 
induced by muscle-specific NAMPT KO27. Furthermore, evidence suggests NAM can 
induce lipotoxicity and glucose intolerance116,117. 
In contrast to NAM, oral NA elevates liver ADP-ribose to a similar extent as NR. 
However, ADP-ribose still remained ~25% greater with NR (n.s. n=3-4)28. Furthermore, 
NA only elevated liver NAD+ AUC half as much as NR. Importantly, NA causes a mild 
to extreme flushing reaction which has reduced compliance in dyslipidemic patients 
taking NA, even with extended release formulations118,119. As well, the time course of 
NAD+ elevation after gavage of NA/NAM/NR suggests that twice daily supplementation 
for any of the precursors would be required to elevate 24-hour NAD+ metabolism28. This 
could be a difficult regimen to maintain given NA’s side effects. In addition, NA has 
been demonstrated to reduce insulin sensitivity120,121 and increase oxidative stress122. 
 NMN has also been used to elevate NAD+ levels and logically appears to be a 
good precursor, given that NR is first metabolized to NMN inside the cell before 
becoming NAD+. However, NMN cannot be transported across the cell membrane and is 
first metabolized to NR extracellularly, before cellular uptake29. Some evidence also 
suggests that NR may be the preferred NAD+ precursor during stress. Nerve transection 
elevated neuronal NRK2 >20-fold123 and we observed an increase in aortic NRK1 after 
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NAMPT KO, suggesting a preference for NR-derived NAD+ during NAD+ deficiency124. 
However, this may be of little importance with oral NMN administration protocols,  as 
NMN is converted to NR in the small intestine25. Still, whereas little is known about the 
absorption of NMN, some oral NR is absorbed intact and directly utilized to create 
NAD+27.  Unlike NMN, NR has undergone a comprehensive safety assessment, including 
administration of doses up to 5000 mg/kg/day125. NR has also been administered in a 
clinical trial and demonstrated to elevate human NAD+ metabolism28. Lastly, although 
not statistically evaluated, oral administration126 and IP injection29 of NR appears to 
increase liver and muscle NAD+ more than NMN. 
In summary, NMN and NR both appear to be promising supplemental NAD+ 
precursors. There is evidence that NR increases NAD+ metabolism and attenuates 
pathology more than NA or NAM. Evidence also suggests that NR may elevate NAD+ 
more than NMN in certain tissues.  
 
1.5  Angiotensin II infusion as a model of hypertension, vascular 
oxidative stress and aging  
 
1.5.1  Mechanism of Ang II-induced oxidative stress and associated vascular pathology 
Decades of research has established the role of the renin-angiotensin system 
(RAS) in hypertension and vascular disease. Ang II is the main bioactive product of the 
RAS and has been widely used to induce experimental vascular pathology both in vitro 
and in vivo127. Ang II acts through angiotensin II type 1 (AT1R) and type 2 G protein-
coupled receptors, which can generally be considered to have pathological and protective 
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downstream effects, respectively127. Through the AT1R, Ang II elevates blood pressure, 
which appears to involve oxidative stress in several tissues. This is associated with a 
blood pressure-independent hyperplasia of the ascending aorta, and aortic medial 
hypertrophy in the thoracic, suprarenal and infrarenal zones128. Furthermore, Ang II 
induces endothelial dysfunction129, cardiac hypertrophy130 and abdominal aortic 
aneurysms in some mouse strains131.  
Through the AT1R, Ang II upregulates NADPH oxidase (Nox) subunits at the 
epigenetic, transcriptional and post-transcriptional level, increasing superoxide 
generation127,132. Nox is a transmembrane catalytic protein, with seven isoforms (Nox1-5, 
Duox1-2) formed through interaction with up to 5 distinct/shared cytosolic regulatory 
subunits133. Nox1, 2, 3 and 5 have been found in ECs and VSMCs133. All vascular cell 
types can use Nox to create superoxide by transferring electrons from NADPH to 
molecular oxygen134. This superoxide directly contributes to oxidative stress, or is 
dismutated into hydrogen peroxide (H2O2)133. Oxidative stress is thought to act locally, as 
O2- is highly reactive, has a short half-life, and cannot passively cross cell membranes134. 
H2O2 on the other hand, has a slightly longer half-life and can cross the plasma 
membrane through aquaporin channels135. Both of these reactive oxygen species (ROS) 
directly react with cellular membranes, proteins and DNA, but can also give rise to other 
ROS. O2- can react with NO forming ONOO-, and H2O2 can form OH- in the presence of 
Fe2+ 127. During Ang II infusion, H2O2 appears to be important in vascular hypertrophy136 
and endothelial dysfunction137, as over/under expression of H2O2 clearing enzymes 
impacts these endpoints. Interestingly, a feed-forward loop exists where Nox-derived 
ROS upregulates AT1R expression138. Furthermore, NO can suppress AT1R expression 
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but as previously mentioned,  reacts with O2-, forming ONOO-138.  
Evidence exists to suggest a critical mediating role of Nox-derived oxidative 
stress in Ang II-induced hypertension. Ang II upregulates vascular Nox1 and its gene 
disruption ~halves Ang II-induced ROS production and hypertension139, with conflicting 
reports on thoracic medial hypertrophy140. KO of Nox-2 reduces baseline blood pressure, 
but does not attenuate Ang II-induced blood pressure elevation, despite abrogating ROS 
and attenuating aortic thickening141. KO of the Nox1/2 regulatory subunit P47phox also 
prevented Ang II-induced vascular ROS production and halved hypertension142. Nox4 
has been reported to exert protective and pathological functions. Meanwhile, less is 
known about Nox5 because it is not present in rodents133. Interestingly, evidence suggests 
neuronal ROS plays an important role in Ang II-induced hypertension. Nox disruption or 
anti-oxidant clearance of ROS in several brain regions lowers Ang II-induced ROS and 
hypertension143,144. Adding complexity, Ang II-induced superoxide production can also 
be blunted through vascular IL6 deficiency145 and Cox-2 inhibition146. 
  
1.5.2  Cell death induced by Ang II  
Cell death is one of the most significant consequences of Ang II-mediated cell 
damage. In vitro work has demonstrated that Ang II can induce apoptosis of ECs147 and 
VSMCs148. As well, apoptosis of smooth muscle cells (cleaved-caspase-3) can be seen in 
vivo during long-term Ang II infusion, which is largely associated with areas of aortic 
hemorrhage149. It is not clear if cell death was a primary outcome of Ang II or secondary 
to hemorrhage-associated adverse microenvironment. In this study, EC apoptosis was not 
quantitatively reported and does not appear present in representative images at day 3, 10, 
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18 or 28149. In rats receiving 7 days of Ang II, aortic DNA laddering increased, indicative 
of apoptosis, and VSMC TUNEL was detected, although not quantified150. Investigators 
have also detected apoptosis in the heart151 and kidney152 after Ang II infusion.  
Little is known about other cell death subroutines that may be stimulated by Ang 
II. This may be due to technical limitations in detection. A recently published abstract 
reported increased aortic smooth muscle cell receptor-interacting protein kinase 3 (RIP3) 
in mice receiving high fat diet and 28 days of Ang II infusion, suggesting that necroptosis 
may be present153. 
Uncontrolled and excessive death of ECs and VSMCs is detrimental to vascular 
homeostasis and health. Therefore, preventing their death during age and disease is an 
important endpoint in combating vascular pathology. Healthy ECs maintain the integrity 
of the vascular wall and secrete vasculoprotective compounds such as nitric oxide 
(NO)154. Loss of these functions during EC death has been proposed to promote 
disease154,155. For instance, loss of ECs increases transendothelial leakage156, which can 
promote uptake of macromolecules such as LDL157 and possibly inflammatory cells158. In 
fact, it has been suggested that endothelial leakiness is responsible for 90% of 
transendothelial LDL transport159. Furthermore, inflammatory cells infiltrating the media 
promote atherosclerosis160, ECM degradation161, and secrete ROS which can damage 
VSMCs162. Moreover, inflammatory signaling from dying ECs or VSMCs may enhance 
these processes163. Evidence also suggests EC death/injury promotes thrombosis by 
releasing platelet activating compounds and exposure of platelets to the endothelial cell 
basement membrane154. One interesting context for endothelial cell injury is malignant 
hypertension, which can lead to thrombosis at the capillary level (thrombotic 
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microangiopathy)164. VSMCs are responsible for maintaining vessel structure/integrity 
and tone. Death of VSMCs has been implicated in aneurysm formation165, atherosclerosis 
and plaque rupture166, pathologies in which elevated Ang II is considered a driving factor. 
 
1.5.3  DNA damage, senescence and inflammation induced by Ang II 
Oxidative stress damages DNA. Ang II infusion has been demonstrated to 
increase oxidation of guanine nucleobases and induce formation of the DNA damage 
response protein γ-H2AX in the kidney167, heart167 and VSMCs167. Biochemically, 
guanine is highly susceptible to oxidation forming 8-oxo-2'-deoxyguanosine (8-oxo-dG), 
one of the most frequent DNA lesions168. If un- or mis-repaired, 8-oxo-dG can cause 
GàT and AàC substitutions. Furthermore, recent work has demonstrated 8-oxo-dG 
lesions can silence transcription, even when occurring at non-transcribed/non-promoter 
DNA regions169. In addition, 8-oxo-dG lesions on promoter sequences promote NF-kB-
driven gene expression170. Single and double strand DNA breaks also pose a risk to 
cellular function. When double strand breaks occur, histone H2AX is phosphorylated 
forming γ-H2AX to facilitate DNA repair171. Therefore, detection of γ-H2AX is 
frequently used to assess the extent of DNA double strand breakage. Mutations from 
unrepaired double strand breaks contribute to cell death, inflammation and senescence172. 
Importantly, these lesions have been detected in human VSMCs at sites of 
atherosclerosis173 and aneurysm174. 
 In vitro, it has been demonstrated that Ang II-induced damage to telomeric and 
non-telomeric DNA contributes to replicative senescence and stress-induced premature 
senescence, respectively175. Consistent with this, VSMC senescence has been detected 
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after infusion of Ang II176,54. Moreover, senescence or a predisposition to senescence is 
seen in VSMCs at sites of atherosclerosis177 and aneurysm178, both of which are 
associated with DNA damage. Senescence is a state of permanent cell cycle arrest. 
Senescent cells promote pathology by disrupting normal tissue structure and function, 
while secreting pro-inflammatory cytokines and matrix-degrading enzymes179. In 
replicative senescence, damage or natural shortening of telomeres exposes chromosomal 
DNA to replication mediated cleavage9. Hence a senescent phenotype is adopted to 
prevent proliferation of dysfunctional cells. In stress-induced premature senescence, 
telomere shortening-independent senescence occurs following prolonged oxidative stress 
and DNA damage9. Although several contributing signaling pathways to senescence 
exist, the p16INK4A pathway was investigated in this project. p16INK4A expression is 
increased during oxidative stress180 and DNA damage181. p16INK4A signals through 
several intermediaries to suppress the expression of S-phase genes, preventing cell cycle 
progression and inducing senescence179. For this reason it is a commonly used biomarker 
of senescence and its expression can be increased by Ang II176. 
Ang II infusion also causes inflammation, which contributes to vascular 
pathology182. One important proinflammatory change is an increase in the expression of 
vascular cell adhesion molecule-1 (VCAM-1) in vascular cells183. Circulating 
inflammatory cells adhere to vessels through adhesion molecules, before transmigration 
into the media, where they promote disease160. VCAM-1 in particular has been implicated 
here184,185. Ang II stimulates cyto-nuclear transmigration of the transcription factor NF-
kB, which promotes expression of VCAM-1. This has been demonstrated in vitro186 and 
during infusion of Ang II183 
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1.5.4  Non-vascular pathology induced by Ang II 
Ang II is a particularly noxious peptide that can induce pathology throughout 
many tissues outside of the vasculature.  Ang II can induce muscle wasting by increasing 
ubiquitin proteasome system-dependent protein degradation through ROS187, IGF-1 
decline188 and inflammation189,190. Muscle is the largest site of glucose disposable191 and 
beyond reducing its size, Ang II induces insulin resistance and plays a role in pancreatic 
pathology192. In fact, after Ang II infusion, end organ damage is seen in tissues including 
the heart, kidney and brain, likely through ROS, inflammation and hemodynamic 
changes193. The kidney in particular is affected by Ang II and is important for the 
development of Ang II-induced hypertension130, 194.  
 
1.5.5  Physiological relevance of high dose Ang II infusion in mice  
Ang II is formed from its precursor angiotensinogen. Therefore, the production 
rate of Ang II cannot exceed the production rate of angiotensinogen. Based on this, it has 
been proposed that an infusion of 1.44 mg/kg/day Ang II to a mouse reflects a 30-fold 
increase over the natural production rate of the Ang II precursor angiotensinogen195. 
Although a high Ang II dose, this may be physiologically relevant stimulus. In the murine 
thoracic aorta, Ang II increases ~25-fold from 2 to 12 months, with a further ~1.4-fold 
increase at 24 months (~35-fold vs. 2 months)196. Although, serum Ang II levels only 
increase from ~30 to ~35 to ~45 pg/ml over this time frame, local Ang II concentrations 
are independently regulated and can be 1000-fold higher than circulating levels197,198. As 
well, thoracic aortic AT1R expression more than doubles between time points (2 vs. 12 
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vs. 24 months) with similar declines in AT2R expression. Assuming 1:1 Ang II to AT1R 
signaling, these changes could reflect up to a >140-fold increase in aortic AT1R signaling 
from 2 to 24 months. In addition to this data, non-human primates exhibit a 5-fold 
increase in aortic intimal Ang II immunostaining with age (6 vs. 20 years)199. Similarly in 
humans, thoracic aortic intimal area fraction of Ang II immunostaining was found to 
increase by ~4-fold (possibly saturated based on representative image) with age (20 vs. 
65 years)200. A 4-fold increase in intimal AT1R protein expression was also noted. 
 Acute increases in blood pressure and oxidative stress occur during hypertensive 
crisis201, in which the RAS has been implicated202,203. Therefore, acute infusion of Ang II 
may represent a model of hypertensive crisis. More sustained infusion, with the 
associated oxidative stress and vascular remodeling, has features of vascular aging. 
 
1.5.6  Ang II infusion and NAD+ metabolism 
Intriguing evidence suggests a link between Ang II signaling and NAD+ 
metabolism. AT1R KO, which improves murine lifespan by 26%, is associated with 
greater kidney NAMPT and SIRT3 mRNA204. Furthermore, 0.3 mg/kg/day Ang II for 14 
days was found to reduce whole heart cell lysate NAD+ by ~33%, which was prevented 
with PARP KO205. Ang II also increases activity of the NAD+ consumer CD38, which 
might contribute to Ang II-induced NAD+ decline99. Importantly, we have found that Ang 
II infusion reduces murine aortic NAD+ and NAMPT content. Furthermore, loss of NAD+ 
homeostasis through KO of NAMPT in VSMCs, promotes aortic pathology110. Given that 
Ang II and AT1R expression increase with age, these studies raise the possibility that 
Ang II contributes to age-associated NAD+ decline. Similarly, more acute vascular 
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damage from Ang II might be linked with impaired NAD+ metabolism.    
Therefore, it is reasonable to consider whether improving NAD+ supply through 
precursor supplementation might protect against Ang II-induced vascular damage. In this 
regard, it is noteworthy that a recent study has demonstrated oral NMN reduces vascular 
oxidative stress, aortic stiffness and  improves endothelial function in aged mice206. In 
addition, cell culture work from our lab has found that NR supplementation partially 
inhibits H2O2-induced vascular cell death, DNA damage, and cell senescence124. Whether 
NR can protect against vascular pathology induced by Ang II is unknown, and a central 
question for this thesis. 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
		
33	
 
 
 
 
 			
 
Figure 1.3 Framework of Ang II-induced pathology and NAD+ decline. 
This figure illustrates the mechanism of Ang II-induced pathology and NAD+ decline. 
Moreover, the contribution of NAD+ decline to pathology is highlighted. Ang II can 
reduce synthesis and increase consumption of NAD+, lowering its levels. ROS also play a 
role in Ang II-induced CD38 activity and NAD+ synthetic machinery decline. Declining 
NAD+ impacts sirtuin activity, exacerbating Ang II-induced pathology. Abbreviations 
used are: Ang II, angiotensin II; NAD+, nicotinamide adenine dinucleotide; ROS, reactive 
oxygen species; VCAM-1, vascular cell adhesion molecule-1; CD38, cluster of 
differentiation 38. 
 
 
 
 
 
 
 
 
 
 
		
34	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		
35	
1.6  Summary of rationale for thesis  
NAD+ homeostasis is vital for vascular cell health. Ang II induces oxidative stress 
and is considered a driver of vascular pathology and disease. Ang II signaling intensifies 
with age and has been demonstrated to suppress NAD+ levels and those of its 
synthesizing enzymes. In vitro, NR can partially protect vascular cells from oxidative 
stress-induced NAD+ decline, death, DNA damage and senescence.  
The objective of my work was to determine whether oral administration of NR 
imparts resistance to Ang II-induced aortic cell damage, in vivo. 
 
1.7  Hypothesis and specific aims 
I hypothesize that nicotinamide riboside administration will protect the aorta from Ang 
II-induced cell death, DNA damage, senescence and, proinflammatory signaling. 
 
To test this hypothesis I will address two aims: 
1. To determine the effect of NR on acute Ang II-induced aortic EC and VSMC 
death and DNA damage 
2. To determine the effect of NR on sustained Ang II-induced aortic EC and 
VSMC DNA damage, proinflammatory signaling and senescence.  
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2  MATERIALS AND METHODS 
2.1  Animals 
Male C57Bl/6 Retired Breeders were ordered from Charles River at 6-9 months of 
age. As these investigations were proof-of-concept, discovery-based research, no formal 
sample size calculation was made. The number of mice in the various treatment groups 
(5-9 for histologic endpoints, 4-14 for physiologic endpoints) was chosen based on an 
assessment of the literature pertaining to Ang II infusion and aortic pathology128,207,208. 
Mice were housed individually, had ad libitum access to food and water and were kept 
under 12 hour light-dark cycles. Mice were given at least one week to acclimate to the 
animal facilities before experiments were performed. Procedures performed were 
approved by Western University, the Animal Care Committee and were done in 
accordance with the Canadian Guide for Care and Use of Laboratory Animals. Only male 
mice were used for this study, as female mice are relatively resistant to Ang II-induced 
pathology209.  
 
2.2  NR administration 
Based on average food intake and body weight, NR-containing food pellets were 
made by mixing NR-containing deionized water (diH2O) with powered Teklad Rodent 
Diet 8604 (naturally containing 64 mg/kg of nicotinic acid, a dose of ~eight mg/kg/day). 
NR capsules (N(r) - NIAGEN®, High Performance Nutrition) were opened and the 
contents were dissolved/vortexed in diH2O before addition to powdered food. Each 
capsule contained 125mg of NR Chloride and was mixed with an appropriate amount of 
		
37	
diH2O/powdered food, to deliver ~400mg/kg/day of NR. This dose has been demonstrated 
to elevate NAD+ levels in multiple tissues (eg. muscle, liver, brown adipose  tissue) and 
studies, with associated benefits126,108,210. Vehicle-treated mice also received homemade 
food pellets, which were made with diH2O. Food was allowed to dry for 24-72 hours 
before administration and was remade every 1-2 weeks.  
 
2.3  3-Day angiotensin II experiments 
Nine- to 10-month old mice were given a NR- or vehicle-containing diet for 1 
week. While continuing their designated diet, osmotic pumps (Alzet model 1003D, Cat#: 
0000289) were implanted subcutaneously on the flank, to continuously infuse 1.44 
mg/kg/day of Ang II (Sigma-Aldrich, Cat#: A9525) or saline for 3 days. Osmotic pumps 
were filled 1-2 hours before implantation, which was performed under isoflurane 
anesthesia. Tail-cuff-derived blood pressure was recorded before diet initiation and 2 
days after osmotic pump implantation (n=7-11 mice). On day 3, mice were euthanized 
and studied for DNA strand breakage (comet assay) (n=106-172 cells from the aortic 
wall), cell death (n=5-8 mice) or liver NAD+ content (n=4-8 mice), as described in the 
appropriate sections below.  
 
2.4  28-Day angiotensin II experiments 
C57Bl/6 mice were followed for 6 weeks to determine baseline blood pressure, 
weight and food intake. Mice were then randomly assigned to receive vehicle-containing 
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diet or NR-containing diet for 3 weeks. After 3 weeks, osmotic pumps (Alzet model 
1004, Cat#: 0009922) were implanted subcutaneously on the flank to continuously infuse 
mice with Ang II (1.44 mg/kg/day) or saline for 4 weeks, while continuing their 
designated dietary treatment. Blood pressure (n=6 mice) and body weight (n=7-14 mice) 
measurements were taken weekly during the study period. After 4 weeks of Ang II, mice 
were anesthetized with isoflurane and euthanized by injection of 1M KCl into the inferior 
vena cava. Animals were perfused with PBS by injection into the left ventricle, after 
which a portion of the liver was excised and frozen in liquid nitrogen for NAD+ assay. 
Whole mouse fixation was performed via cardiac infusion of 4% formaldehyde. Tissues 
were processed for histology, as described below, then investigated for medial thickening 
(n=6-9 mice), DNA oxidation (n=6-9 mice), VCAM-1 (n=6 mice) and p16INK4A (n=5-6 
mice). Ang II/saline delivery was verified by measuring remaining osmotic pump volume 
to ensure pump contents had been dispensed. 
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Figure 2.1 Experimental timeline for 3-day and 28-day Ang II experiments  
A. C57Bl/6 (9-10 month-old retired breeders, Charles River, n=4-11) mice were pre-
treated with NR- (400 mg/kg/day) or vehicle-containing diet for 1 week. While 
continuing their designated treatment, an osmotic pump was implanted subcutaneously, 
infusing saline or Ang II (1.44 mg/kg/day) for 3 days. After 3 days, mice were sacrificed 
and tissues/cells were collected for histology, comet assay, or NAD+ assay. B. C57Bl/6 
(7-10 month old retired breeders, Charles River, n=5-14) mice were pre-treated with NR-
diet (400 mg/kg/day) or vehicle-diet for 3 weeks. While continuing their designated 
treatment, Ang II (1.44 mg/kg/day) or saline was delivered for 4 weeks. Mice were then 
euthanized and tissues were harvested for histological analysis. Blood pressure 
measurements were taken twice a week, on the same days and at the same time, for the 
duration of the study. 
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2.5  In vivo cell death assay 
Following dietary treatment and 3 days of Ang II, mice were anesthetized via 
isoflurane inhalation and injected intravenously with Ethidium Homodimer-III (EthD-III, 
300µM in PBS, Biotium, Cat#:40050) through the dorsal penile vein. After 10 minutes, 
mice were killed via isoflurane overdose and perfused with PBS through the myocardium 
for ~5 minutes. The liver was collected for NAD+ assay and immediately frozen in liquid 
nitrogen. Mice were then infused with 4% formaldehyde through the left ventricle, for 10 
minutes to fix tissues. The ascending, thoracic and suprarenal aorta were excised and 
frozen in OCT. Heart, liver and kidney tissue was also collected and frozen in OCT.  
 
2.6  Acute aortic cell isolation and comet assay 
Following dietary treatment and 3 days of Ang II, mice were euthanized via 
isoflurane overdose, the chest cavity was opened, and the aorta was flushed with PBS 
through the left ventricle. The aorta was excised, ligated distally near the 
thoracoabdominal transition zone and placed in a petri dish containing culture media 
(M199). To isolate ECs, collagenase II (480 units/ml in M199, Worthington) was injected 
into the lumen through the proximal opening and the aorta was incubated at 37°C for 35 
minutes. The ligation was removed and the lumen was flushed with M199 to collect ECs. 
The aorta was kept on ice while ECs were counted, filtered through a cell 70-µm cell 
strainer, and processed for comet assay. Next the aorta was cleaned of adventitia, placed 
in a collagenase I (260 units/ml in M199, Worthington) + dispase (1.8 units/ml in M199, 
Worthington) solution, cut finely using scissors and incubated at 37°C for 1.5 hours. 
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Liberated VSMCs were counted, filtered through a 100-µm pore-size cell strainer and 
processed for comet assay. Cells were protected from light and comet assay was 
performed according to the manufacturer’s instructions (Trevigen, Cat#:4250-050-K), 
with electrophoresis performed at 4°C. Cells were stained with Sybr-Gold to visualize 
DNA and fluorescent images were captured (Olympus BX51 microscope). Open Comet 
plugin for ImageJ was used for analysis and supplemented with manual analysis when 
necessary.  
 
2.7  Blood pressure measurements  
Blood pressure measurements were taken using tail-cuff non-invasive volume-
pressure recording with CODA 6 software (Kent Scientific). Measurements were taken at 
the same time of day within each cohort of animals. Animals were brought to the blood 
pressure room one hour before measurements to reduce stress from transport. Mice were 
loaded in holders and placed on a heating block, which was set on low. Recording cuffs 
were placed on the tail and mice were given 15 minutes to acclimate. Five acclimation 
and 30 blood pressure measurements were recorded, the latter of which were averaged to 
give the daily recorded blood pressure. 
 
2.8  NAD+/NADH assay 
Liver NAD+ levels were determined using a colorimetric kit (Biovision, Cat#: 
K337). The assay measures NADH and relies upon an enzymatic cycling reaction, which 
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converts extracted NAD+ into NADH.  By loading samples with decomposed and intact 
NAD+, NAD+ concentration can be measured indirectly, as the difference in measured 
NADH concentration. To extract tissue NAD+/NADH, 20 mg of tissue was homogenized 
(QIAshredder) in 800 uL of lysis buffer. Samples were then spun at 4°C at 16,000g for 
10 minutes. Supernatants were transferred to a new tube from which 500 uL was loaded 
in 10-kDa Spin Columns and spun at 4°C at 12,000g for 30 minutes to deproteinize 
samples. Remaining supernatant was used for BCA protein assay (PierceTM BCA protein 
assay kit, Thermo Fischer Scientific). In a 96 well plate, 15-40 µL of filtrate and 
decomposed filtrate (heated at 60°C for 30 minutes to decompose NAD+) were loaded in 
duplicate. Wells were brought up to 50 µL using lysis buffer and a NADH standard curve 
was loaded (0-100 pmol/well). 100 uL of cycling mix was added to each well and the 
plate was mixed and incubated at room temperature for 5 minutes. Next, the reaction was 
started by adding 10 uL of NADH developer to each well and was left to cycle at room 
temperature for 1 hour. After 1 hour, absorbance at 450 nm was read on a colorimetric 
plate reader (Thermo Electron Corporation, Multiskan Ascent software).  
 
2.9  Processing of formaldehyde-fixed tissue and delineation of aortic 
regions  
After infusing mice with 4% formaldehyde, tissues were excised, left in 4% 
formaldehyde overnight and subsequently immersed in 70% ethanol. The aorta was 
cleaned, cut into ascending/thoracic/suprarenal regions, embedded in paraffin and five-
µm cross-sections were cut. The ascending aorta was defined as the region located one to 
three mm distal of the termination of the aortic valve leaflet stubs. The thoracic aorta 
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comprised the region five to seven mm posterior of the left subclavian artery. The 
suprarenal region was located two mm above of the superior mesenteric artery. These 
precise sites were also used when collecting frozen sections of the aorta. 
 
2.10  Cell death (EthD-III) visualization and quantitation 
After freezing aortic tissue in OCT, 10-µm cross-sections were made from the 
ascending, thoracic and suprarenal aortic regions. Sections were mounted with DAPI-
containing media (DAPI Fluoromount-G®, Southern Biotech), sealed with nail polish 
and allowed to dry for 20 minutes. Fluorescent images of EthD-III (λEx/λEm: 530/620 
nm) and DAPI (λEx/λEm: 350/455 nm) were taken immediately and stacked using 
ImageJ. File IDs were blinded using NameChanger (MRR Software) before 
quantification was performed. DAPI signal was used to identify cells, which were 
considered positive when exhibiting EthD-III signal intensity above levels seen in elastin 
background.   
 
2.11  Cleaved caspase-3 immunostaining of frozen sections 
Immunostaining for cleaved caspase-3 was performed on frozen thoracic cross-
sections from mice infused with Ang II for 3 days. A frozen section of liver from an Ang 
II-infused mouse was also stained as a positive control. Sections were exposed to H2O2 
for 30 minutes before 1 hour block with donkey serum (Sigma) and subsequent overnight 
incubation with rabbit polyclonal anti-cleaved-caspase-3 (1:50, Cell Signaling 
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Technologies, Cat#: 9661S). To detect bound primary against cleaved-caspase-3, HRP-
conjugated donkey anti-rabbit secondary antibody (1:200, Vector Labs) was applied for 2 
hours and visualized with DAB (Vector Labs). Haematoxylin counterstaining was 
performed to label nuclei. Sections were thoroughly investigated and light micrographs 
were obtained (Olympus BX51 microscope).  
 
2.12  H&E staining & morphology quantitation 
Five-micron formaldehyde-fixed paraffin-embedded sections from the ascending, 
thoracic and suprarenal aorta were stained with H&E (Leica Autostainer XL). Light 
micrographs were captured using a 20x objective (Olympus BX51 microscope) and 
stitched together using Grid/Collection stitching211 in FIJI, to create full circumference 
cross-sectional images of the aorta. These images were used to quantify histological data. 
The medial area was quantified by measuring the area within the inner and outer most 
elastin layer, using ImageJ. Areas of branching or hemorrhage were avoided and the 
lumen perimeter of quantified zones was used to standardized medial area measurements.   
 
2.13  Immunostaining of formaldehyde-fixed paraffin-embedded 
sections 
Immunostaining was performed on 5-micron paraffin-embedded thoracic cross-
sections from mice infused with Ang II for 28 days. Briefly, slides were deparaffinised 
and antigen retrieval (Retriever 2100, Prestige Medical) was performed with 100 mM 
sodium citrate buffer. Sections were blocked with H2O2 for 30 minutes before 1 hour 
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block with sheep or donkey serum (Sigma) as appropriate and subsequent overnight 
incubation with the primary antibody for the investigated molecular target. Primary 
antibodies included: mouse monoclonal anti-8-oxo-dG (1:300, Northwest Life Sciences, 
NWA-MOG020), rabbit polyclonal anti-VCAM-1 antibody (1:30, Santa Cruz, Cat#:sc-
1504-R) and mouse monoclonal anti-p16INK4A (1:500 Santa Cruz, Cat#:sc-1661). To 
detect bound primary antibody, HRP-conjugated sheep anti-mouse or HRP-conjugated 
donkey anti-rabbit secondary antibody (1:200, Vector Labs) was applied for 2 hours and 
visualized with DAB (Vector labs). 8-oxo-dG and p16INK4A stained sections were 
counterstained with haematoxylin. Light micrographs were captured, files IDs were 
blinded using NameChanger (MRR Software) and quantitation was performed. Positive 
cells were identified by brown DAB signal within the nucleus. One section was 
quantified per animal. For p16INK4A, two slides containing aortic sections were stained 
from each animal and positivity was determined by averaging the percentage of positive 
cells from one section on each slide. For VCAM-1, a threshold was chosen using ImageJ, 
which captured DAB signal lining the endothelium without capturing the adjacent elastin. 
This threshold was applied to all images and used to measure the area of DAB signal. 
This area was then standardized to the perimeter of the aorta. 
 
2.14  Statistical analyses  
Statistical differences (P < 0.05) were determined using GraphPad Prism software 
version 6.0. Unless otherwise stated below, One-Way ANOVA was used to assess the 
effects of one independent variable on a dependent variable. This test was followed by 
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Dunnett’s Multiple Comparison Test, comparing Saline and NR+Ang II groups, to Ang 
II. For non-uniform data, Kruskal-Wallis Non-Parametric One-Way ANOVA was used to 
assess the effects of one independent variable on a dependent variable (Fig. 3.1A, 3.2C). 
This test was followed by Dunn’s Multiple Comparisons Test, comparing Saline and 
NR+Ang II groups, to Ang II. 
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3  RESULTS 
 
3.1  Dietary NR supplementation augments liver NAD+ levels during 
Ang II infusion  	
A decline in cellular NAD+ levels has been observed during conditions of 
oxidative stress212,213. Ang II can be damaging to the vasculature and may lower NAD+ 
levels. To determine if NR supplementation impacts Ang II-induced vascular damage, I 
conducted experiments whereby middle-aged C57Bl/6 mice were given a chow diet 
supplemented with NR (400mg/kg/day) or vehicle for 1 week. While continuing their 
respective diet, mice then received a continuous infusion of Ang II (1.44 mg/kg/day) for 
three days. A group of vehicle-treated mice was also infused with saline for three days, as 
control. I first evaluated whether this Ang II infusion protocol affected NAD+ 
metabolism. For this, mice were sacrificed after three days of Ang II and liver NAD+ 
content was assayed. I found that Ang II infusion decreased liver NAD+ content to 55.2% 
of that present in saline-infused mice (p=0.1068, Fig. 3.1A). In contrast, Ang II-infused 
mice that received NR did not have a decrease in NAD+ content. Liver NAD+ content in 
these mice was significantly higher than in Ang II-infused mice on control diet 
(p=0.0321).  
 
3.2  Dietary NR supplementation does not abrogate Ang II-induced 
hypertension 
Ang II infusion elevates blood pressure214. Therefore, I next tested the effect of 
NR on blood pressure during Ang II infusion. In mice implanted with a 3-day Ang II 
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infusion pump, systolic blood pressure on day 2 had increased by 16.6% (~20 mmHg) 
(p<0.01) (Fig. 3.1B). Notably, there was a similar increase in BP in mice on the NR-
supplemented diet (Fig. 3.1B). 
I also measured blood pressure in mice implanted with 28-day Ang II infusion 
pumps. Blood pressure on day 27 of Ang II infusion in mice receiving vehicle-diet 
increased by ~30 mmHg (p<0.01) (Fig 3.1C). Again however, an NR-diet had no impact 
on systolic blood pressure increase in response to Ang II. 
 
3.3  Dietary NR supplementation does not affect Ang II-induced 
bodyweight decline  
Ang II infusion can also lead to body weight loss. This is reportedly due to 
anorexia215 and muscle wasting216, which can be mitigated by AT1R blockers217. I 
therefore tested if NR administration could impact bodyweight. At baseline, body weight 
was not significantly different between treatment groups (~30g). After four weeks of Ang 
II infusion, body weight was ~four grams lower in Ang II-infused mice compared to 
saline-infused mice (p<0.05, Fig. 3.1D). However, NR-diet did not impact this body 
weight disturbance (p=0.9330). 
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Figure 3.1 NR can maintain NAD+ levels during Ang II infusion, but does not affect 
hypertension or bodyweight disturbance A-B. Liver NAD+ levels (A, n=4-8, 
†p=0.0321 vs. Ang II) and tail-cuff systolic blood pressure measurements (B, n=7-11, 
*p=0.006 vs. Saline) from C57Bl/6 mice receiving vehicle- or NR-containing diet for 10 
days, with Ang II- or saline-infusion during the last 3 days. Blood pressure was measured 
on day 2 of infusion. Values are the mean ± S.E.M. C-D. Tail-cuff systolic blood 
pressure (C, n=6, *p=0.009 vs. Saline) and body weight measurements (D, n=7-14, 
*p=0.0415 vs. Ang II) from C57Bl/6 mice receiving vehicle- or NR-containing diet for 3 
weeks, followed by infusion of Ang II or saline for 28 days, while staying on the 
designated diets. Blood pressure was taken on day 27 of infusion. Body weight was taken 
at baseline (before diet initiation) and on day 27 of infusion. Values are the mean ± 
S.E.M. 
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3.4  Dietary NR protects aortic vascular cells from acute Ang II-induced 
death, in vivo 
Ang II induces apoptosis of vascular cells in vitro147,218 and during sustained 
infusion in mice149. However, the true extent of Ang II-induced cell death, which may 
occur through many non-apoptotic routines, is unknown. Furthermore, it is not known if 
an acute infusion of Ang II can induce cell death or if supplementation with NR has any 
protective effect.  Therefore, we used a vital dye to investigate Ang II’s effect on vascular 
cell viability, and whether NR has any impact. To do this, mice were treated with NR- or 
vehicle-diet for 1 week, before also receiving a continuous infusion of Ang II or saline 
for 3 days. Ten minutes before sacrifice, mice were injected intravenously with the vital 
dye, Ethidium Homodimer-III (EthD-III). EthD-III is a cell membrane impermeable dye, 
which fluoresces red upon binding with DNA. Because EthD-III is cell membrane 
impermeable, it can only enter dead/damaged cells, which have a compromised cell 
membrane219. After sacrifice, the aorta was harvested, frozen in OCT and cryosections 
were obtained. Cross-sections of the ascending, thoracic and suprarenal aorta were 
mounted with DAPI-containing media and EC/VSMC EthD-III positivity was assessed. 
This revealed that Ang II induced marked EC death in the ascending, thoracic and 
suprarenal aorta. This death response was attenuated by NR supplementation (Fig. 3.2A). 
On average, EthD-III-positive ECs increased from 4.1% in saline to 43.4% in mice 
subjected to Ang II infusion (p=0.0005, Fig. 3.2B). With NR treatment, EC EthD-III 
positivity decreased to 10.7% (p=0.0012). 
 The ascending, thoracic and suprarenal aorta also exhibited a significant increase 
in VSMC EthD-III positivity upon 3 days of Ang II infusion (Fig. 3.2C). In the thoracic 
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aorta, NR administration significantly reduced the number of EthD-III-positive cells 
(p=0.0275). On average, EthD-III-positive VSMCs increased from 0.3% in saline-infused 
mice to 12.1% in Ang II-infused mice (p=0.0321). With NR supplementation, only 2.8% 
of VSMCs exhibited EthD-III positivity (p=0.0571).  
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Figure 3.2 NR protects vascular cells from acute Ang II-induced death and 
membrane permeability A. Fluorescent images depicting EthD-III (red), elastin 
background (green) and DAPI (blue) signal, from the thoracic aorta of mice treated with 
NR- or vehicle-diet for 1 week, before also receiving a continuous infusion of Ang II or 
saline for 3 days. B-C. Quantitation of the percentage of EthD-III-labeled ECs (B, n=5-8, 
*p=0.0003, **p=0.0075, ***p=0.00128, ****p=0.0005 vs. Saline. †p=0.0047, ††p=0.0046, 
†††p=0.0018, ††††p=0.0012 vs. Ang II) and VSMCs (C, n=5-8, *p=0.0053, **p=0.0004, 
***p=0.0116, ****p=0.0321 vs. Saline. †p=0.0275 vs. Ang II) Bars represent mean ± 
S.E.M. 
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3.5  Ang II-induced death at day 3 is caspase-3-independent 
Long-term Ang II infusion can induce apoptosis in vascular cells of the aorta149. 
We stained for the apoptotic mediator cleaved caspase-3, to determine whether cell death 
at day 3 of Ang II occurs through a caspase-3-dependent apoptosis program. In the 
ascending, thoracic and suprarenal aorta, ECs and VSMCs in all treatment groups did not 
stain positively for cleaved caspase-3 (Fig. 3.3). A liver section from an Ang II-infused 
mouse was used as a positive control, which stained positively for cleaved caspase-3 
(Fig. 3.3, middle panel).  
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Figure 3.3 Acute Ang II-induced EC and VSMC death is caspase-3-independent A. 
Cleaved caspase-3 immunostaining in the thoracic aorta of mice fed a diet with NR or 
vehicle for 1 week, before also receiving a continuous infusion of Ang II or saline for 3 
days. Positive control represents a sample of liver taken from an Ang II-infused mouse. 
Staining was performed in the ascending, thoracic and suprarenal aorta and appeared 
negative in each.   
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3.6  NR protects aortic vascular cells from acute Ang II-induced DNA 
damage  
Ang II can induce DNA strand breakage167. In vivo, this has been assessed only 
indirectly by measuring levels of DNA damage response proteins176. As yet, there is no 
direct evidence that Ang II can cause DNA strand breakage in ECs or SMCs within the 
vessel wall. To assess this, I developed a strategy that builds on the “comet assay”. The 
comet assay uses gel electrophoresis to pull cleaved DNA - which has lost its 
supercoiling, exposing its negative charge - from the nucleus. This forms a comet shaped 
structure, with intact DNA in the “head” and damaged DNA in the “tail”220. Previous in 
vitro work in our lab has demonstrated that NR can protect vascular cells from H2O2-
induced DNA damage.  To investigate NR’s effect on Ang II-induced DNA damage, in 
vivo, mice received a NR- or vehicle-containing diet for 1 week, before also receiving a 
continuous infusion of Ang II or saline for 3 days. After 3 days, mice were euthanized 
and ECs were immediately collected by exposing the aortic lumen to collagenase II for 
35 minutes at 37°C. To collect VSMCs, the aorta was cleaned of adventitia and digested 
in collagenase I and dispase. Comet assay was then performed on the acutely dispersed 
cells. This revealed that, remarkably, short term Ang II infusion induced DNA damage in 
both ECs and VSMCs (Fig. 3.4A). Importantly, in mice receiving NR in the diet, both 
cells types displayed reduced DNA cleavage. Compared to saline infusion, ECs from Ang 
II-infused mice exhibited a 4.1-fold increase in tail moment (p<0.001). However, cells 
from NR-supplemented mice exhibited a 41.6% reduction in tail moment following Ang 
II infusion (p<0.0001). Similarly, Ang II infusion resulted in VSMCs exhibiting a 3.5-
fold increase in tail moment (p<0.0001). Like for ECs, this DNA damage was reduced by 
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40.1% in mice receiving the NR-diet (p=0.0158). 
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Figure 3.4 NR protects aortic vascular cells from Ang II-induced acute DNA 
damage A. Sybr-Gold staining, depicting comet tails of ECs and VSMCs isolated from 
mice that had received a diet containing NR or vehicle for 1 week before also receiving a 
continuous infusion of Ang II or saline for 3 days. B-C. Quantitation of tail moments 
from ECs (B, n=142-172 cells from 2 mice per condition, *p<0.0001 vs. Saline, 
†p<0.0001 vs. Ang II) and VSMCs (C, n=106-180 cells from 1 saline mouse and 2 mice 
from Ang II infused groups, **p<0.0001 vs. Saline, ††p=0.0158 vs. Ang II) using open 
comet software. Bars represent mean ± S.E.M. 
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3.7  NR confers site-specific reduction in Ang II-induced medial 
thickening  
 
Chronic Ang II infusion results in thickening of the aortic media. Having shown 
that early cell death can be prevented by NR, I next investigated whether medial area 
after 28 days of Ang II infusion was affected by NR pre- and co-treatment. After Ang II 
infusion, medial area in the ascending, thoracic and suprarenal aorta was significantly 
increased (Fig. 3.5A to C). Interestingly however, NR treatment did not impact medial 
area in the ascending or thoracic aorta. On the other hand, NR did confer mild protection 
in the suprarenal region. Compared to saline-infused mice, ascending aortic medial area 
in mice receiving either Ang II or Ang II plus NR pre- and co-treatment, was increased 
by 37.6% and 39.7% respectively (p<0.05) (Fig. 3.5D). Similarly, in the thoracic aorta, 
medial area was 43.6% and 42.1% greater in mice receiving Ang II and Ang II plus NR 
treatment, respectively (p<0.01, Fig. 3.5E). However, in the suprarenal aorta, Ang II 
infusion resulted in a 52% increase in medial area, but in mice administered NR, this 
increased by only 29.3% (p=0.0335). 
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Figure 3.5 NR confers site-specific reduction in Ang II-induced medial thickening  
A-C. H&E staining of ascending (A) thoracic (B) and suprarenal (C) aortic sections from 
mice on a diet supplemented with vehicle or NR and subjected to 4 weeks of Ang II 
infusion (n=6-9). D-F. Quantification of medial area, standardized to lumen perimeter 
from the ascending (D, *p=0.0051 vs. Saline) thoracic (E, **p=0.0022 vs. Saline) and 
suprarenal aorta (F, ***p=0.0003 vs. Saline. †p=0.0335 vs. Ang II). Bars represent mean ± 
S.E.M. 
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3.8  NR attenuates Ang II-induced DNA damage in vascular cells at day 
28 
I next asked whether NR pre- plus co-treatment would protect vascular cells from 
genomic damage accumulated after prolonged infusion of Ang II. For this, I 
immunostained the thoracic aorta for the DNA damage biomarker, 8-oxoguanine (8-oxo-
dG), following 28 days of Ang II infusion. 8-oxogaunine is a DNA damage product, 
formed when guanine nucleobases undergo oxidation168. Ang II significantly increased 
the percentage of 8-oxo-dG-positive ECs (Fig. 3.6A, B) and VSMCs (Fig. 3.6A, C) in the 
thoracic aorta (3.8% vs. 51.7% in ECs p=0.0042, 7.1% vs. 30.3% in VSMCs p=0.0012). 
However, Ang II-infused mice supplemented with NR exhibited a significant reduction in 
the percentage of 8-oxo-dG-positive cells (51.7% vs. 22.6% in ECs p=0.0042, 30.3% vs. 
10.8% in VSMCs p=0.0227). 
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Figure 3.6 NR attenuates Ang II-induced DNA oxidative damage in vascular cells  
A. Light micrographs depicting 8-oxo-dG immunostaining in the thoracic aorta of mice 
infused for 4 weeks with saline, Ang II, or Ang II with pre-treatment (3 weeks) and co-
treatment (4 weeks) with NR (n=6-9). Arrows indicate 8-oxo-dG-positive cells. B-C. 
Percent of 8-oxo-dG-positive ECs (B, *p=0.0042 vs. Saline, †p=0.0069 vs. Ang II) and 
VSMCs (C, **p=0.0012 vs. Saline, ††p=0.0227 vs. Ang II) in thoracic aortic sections. Bars 
represent mean ± S.E.M. 
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3.9  NR prevents Ang II-induced endothelial VCAM-1 expression 
VCAM-1 has been implicated in several inflammatory diseases, including 
atherosclerosis221. Expression of VCAM-1 increases during Ang II infusion222. To 
determine if NR impacts this, immunostaining for VCAM-1 was performed in the 
thoracic aorta, following 28 days of Ang II infusion (Fig. 3.7A). Endothelial cell VCAM-
1 expression was 2-fold higher in Ang II-infused mice compared to saline-infused mice 
(Fig. 3.7B) (p=0.0092). Treatment with NR completely abrogated this increase 
(p=0.0153).  
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Figure 3.7 NR prevents Ang II-induced endothelial VCAM-1 expression A. VCAM-1 
immunostaining in the thoracic aorta of mice infused for 4 weeks with saline, Ang II, or 
Ang II with pre-treatment (3 weeks) and co-treatment (4 weeks) with NR. B. 
Quantification of VCAM-1-positive area lining the endothelium, standardized to intimal 
perimeter, and expressed relative to the signal in saline-infused mice. Bars represent 
mean ± S.E.M. (n = 6 mice, *p=0.0092 vs. Saline, †p=0.0153 vs. Ang II).  
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3.10  NR ameliorates Ang II-induced p16INK4A expression 
Prolonged oxidative stress and DNA damage can result in cellular senescence223. 
In vitro work in our lab has demonstrated NR can protect ECs and VSMCs from H2O2-
induced senescence124. Therefore, I next investigated whether NR impacted Ang II-
induced senescence  in vivo, by performing immunostaining for the senescence 
biomarker, p16INK4A. p16INK4A is a tumor suppressor that induces cell cycle arrest and is 
therefore commonly used to identify senescent cells223. As depicted in Fig. 3.8, the 
percentage of p16INK4A-positive ECs and VSMCs was significantly higher in Ang II-
infused mice compared to that observed in saline-infused counterparts (26.6% vs. 8.8% in 
ECs p=0.0109, 40.4% vs. 13.1%. in VSMCs p=0.0022) (Fig. 3.8B). Treatment with NR 
reduced p16 INK4A positivity in both ECs (8.5% vs. 26.6% p=0.0097) and VSMCs (22.3% 
vs. 40.4% p=0.0398). 
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Figure 3.8 NR ameliorates Ang II-induced p16INK4A expression A. p16INK4A 
immunostaining in the thoracic aorta of mice infused for 4 weeks with saline, Ang II, or 
Ang II with pre-treatment (3 weeks) and co-treatment (4 weeks) with NR (n=5-6). 
Arrows indicate p16INK4A-positive cells B-C. Quantification of p16INK4A-positive ECs (B, 
*p=0.0109 vs. Saline, †p=0.0097 vs. Ang II) and VSMCs (C, **p=0.0022 vs. Saline, 
††p=0.0398 vs. Ang II ) in whole aortic cross-sections. Bars represent mean ± S.E.M.  
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4  DISCUSSION 
The major findings of this thesis are:  
1. In middle-aged mice infused with Ang II, oral NR administration elevates 
liver NAD+ content. 
2. Administration of NR does not impact the immediate or sustained blood 
pressure rise induced by Ang II in middle-aged mice, nor prevent body weight 
loss induced by sustained Ang II infusion. 
3. Ang II infusion induces aortic EC and VSMC death. This early death response 
is prevented by NR administration.  
4. Administration of NR inhibits oxidation of DNA, VCAM-1 expression, and 
senescence in ECs and VSMCs, induced by chronic Ang II infusion. 
 
4.1  Oral NR supplementation augments liver NAD+ in mice infused 
with Ang II 
During oxidative stress and aging, NAD+ levels decline. This has the potential to 
impair the activity of proteins important to cellular health and function100. To counteract 
this, several precursors to NAD+ have been synthesized or purified and studied to 
ascertain if their delivery productively boosts NAD+ synthesis41. In 2012, Canto et al. 
demonstrated that oral NR administration increases NAD+ levels in several tissues in 
mice126. I employed a similar feeding protocol and show that Ang II-infused mice that 
were fed a diet with NR had higher liver NAD+ content than those subjected to Ang II 
and fed a vehicle-diet. This is the first study to report a NR-mediated augmentation of 
liver NAD+ in mice infused with Ang II. This finding provides assurance that the NR-
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containing diet was properly prepared and administered, and mice receiving NR utilized 
it to generate NAD+. Although vascular cell NAD+ measurements would be desirable, the 
aorta contains relatively few cells, making measuring NAD+ and detecting differences in 
NAD+ difficult. For instance, despite demonstrating impressive vascular benefits, a study 
administering an alternative precursor  (NMN) to aged mice did not detect an increase in 
aortic NAD+206. The authors speculate this was due to rapid metabolism of generated 
aortic NAD+. Another study sought to measure NAD+/NADH ratios in the heart after NR 
treatment but did not report these values because they were deemed “unreliable”224. In a 
third study, NMN administration led to a non-significant trend to increase NAD+ in liver, 
skeletal muscle, cortex and brown adipose tissue225. The authors noted the difficulty of 
measuring small fluctuations in NAD+ and used labeled NMN to confirm its contribution 
to the tissue NAD+ pool.  
In keeping with my finding with respect to Ang II and NAD+, experiments in 
vitro, have revealed a rescuable decline in VSMC NAD+ after 3 days of Ang II176. 
Similarly, in vitro work in our lab has demonstrated NR delivery increases NAD+ content 
and buffers NAD+ decline in ECs and VSMCs exposed to H2O2124. 
 
4.2  NR does not impact Ang II-induced hypertension 
Certain hypertensive medications can lower Ang II-induced hypertension in mice, 
particularly those that block RAS signaling226,227. I demonstrated that NR has no impact 
on acute and chronic Ang II-induced hypertension in middle-aged C57Bl/6 mice. 
Consistent with this, administering the NAD+-boosting compound, PNU-282987, did not 
impact tail-cuff-derived blood pressure after 14 days of Ang II (0.576 mg/kg/day)176. 
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Furthermore, CD38 KO, an intervention that can markedly increase NAD+ levels, did not 
abrogate the rise in tail-cuff-derived blood pressure induced by 2.16 mg/kg/day of Ang II 
for 14 days228.  
On the other hand, human data has raised the possibility that NAD+ precursors 
may provide mild blood pressure lowering in subsets of patients. In humans, the NAD+ 
precursor niacin has been used to treat dyslipidemia for several decades. In dyslipidemic 
patients administered 1-2 g/day of niacin, systolic/diastolic blood pressure (SBP/DBP)  
was reduced by ~2/3 mmHg after 24 weeks229. In another trial, there was no reduction in 
BP with 3 g/day of niacin in MI survivors230, but a post-hoc analysis suggested a 3/2 
mmHg decline in SBP/DBP in patients considered to have metabolic syndrome231. In 
contrast, of five studies administering niacin combined with other drugs to patients with 
cardiovascular disease, only one found a decrease in blood pressure232. Collectively, these 
studies suggest that NR’s anti-hypertensive potential should not be ruled out entirely, 
particularly in the context of metabolic syndrome/dyslipidemia. However, our results 
demonstrate that in the context of aggressive Ang II delivery, BP is not affected by NR. 
This is noteworthy because despite this ongoing hypertensive milieu, NR was found to 
protect vascular cells from pathology, discussed below.  
 
4.3  NR does not impact Ang II-induced body weight decline  
Skeletal muscle wasting occurs during chronic heart failure (CHF) and is an 
independent risk factor for mortality in these patients233,234. Ang II is elevated in CHF235 
and its infusion in mice results in skeletal muscle atrophy/cachexia236. In our study, Ang 
II infusion resulted in body weight loss. However, this was not impacted by NR 
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treatment.  In agreement with this, mdx-muscular-dystrophy mice treated with NR did not 
increase bodyweight, lean mass, or lower limb muscular wet weight, despite an increase 
in muscle NAD+114. Following hepatectomy237 or intracerebral hemorrhage238, NR/NMN 
did promote bodyweight gain,  although this may be secondary to other functional 
improvements.  
It is possible in my study that NR did not elevate muscle NAD+ levels, that 
declined in response to Ang II infusion. NAD+ does appear to be important for the 
maintenance of bodyweight and lean mass, which are reduced in mice with muscle-
specific NAMPT KO27. These mice exhibit severe skeletal muscle NAD+ depletion 
(~0.75 vs. ~0.18 nmol/mg) and when treated with NR, only a non-significant trend to 
increase muscle NAD+ (~0.25 nmol/mg) or muscle mitochondrial NAD+ was observed. 
Using an isotope-labeled NR tracer, the authors found that NR was directly utilized to 
synthesize NAD+ in the liver, but in muscle, NR was largely converted to NAM, with a 
minor indirect contribution to the muscle NAD+ pool. This suggests that NR may be less 
effective at elevating NAD+ in skeletal muscle, particularly when NAMPT expression is 
reduced. Several studies have demonstrated increased muscle NAD+ following NR/NAD+ 
precursor administration126,114,29. But the aforementioned data raises the possibility that 
NR did not elevate muscle NAD+ levels during the systemic oxidative stress of Ang II 
infusion. 
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4.4  NR abrogates acute Ang II-induced cell death within the aortic wall 
Oxidative stress increases with age and has been implicated in several age-related 
diseases, including vascular disease239. Reductions in NAD+ have been observed during 
oxidative stress and linked to cell death212. Our lab has demonstrated that overexpression 
of the NAD+ generating enzyme, NAMPT, improves survival of vascular cells during 
oxidative stress240,241. Furthermore, in vitro work has demonstrated that administration of 
NR can protect cells from H2O2-induced death124. In the current study, NR was orally 
administered to mice infused with Ang II. I found that this protected ECs and VSMCs 
from acute Ang II-induced death. 
This was the first study using a vital dye to investigate vascular cell death in an 
Ang II infusion model. In doing so, I am the first to report that an acute infusion of Ang 
II induces EC and VSMC death. This data, coupled with a lack of staining for the 
apoptotic mediator cleaved caspase-3, provides the first evidence for a non-apoptotic 
death response to Ang II infusion. This is particularly noteworthy as Ang II infusion has 
been used for decades to induce experimental pathology and this finding expands our 
understanding of Ang II’s pathological effects. 
To label dead cells, I used EthD-III, as it has been used to label dead endothelial 
cells in vivo, and importantly is a sensitive marker of death242 - reduced to near non-
detectable levels by chemical/genetic suppression of cell death mediators242. EthD-III is a 
cell membrane impermeable dye, therefore cells that uptake EthD-III have lost their 
plasma membrane integrity, fulfilling one of the in vitro criterion needed to consider cells 
dead, as established by the Nomenclature Committee on Cell Death243. EthD-III allows 
detection of cell death regardless of the mode of death. Furthermore, currently used 
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molecular markers of cell death can be transient, may not necessarily reflect the true 
incidence of cell death and only inform on specific death routines. 
 Vital dyes based on membrane permeability have been used for decades to assess 
cell viability244,245, although generally not in vivo. This is a strength of my study. It 
should nonetheless be considered that an increase in membrane permeability may reflect 
repairable damage to the cell membrane246. Therefore, I cannot exclude the possibility 
that some of the EthD-III-positive cells were stressed but may have recovered.  
Improvements in cell survival have been demonstrated with delivery of NAD+ 
and certain NAD+ precursors in models of acute kidney injury105, liver injury247, 
intracerebral hemorrhage238, spinal cord I/R injury248, Alzheimer’s disease249 and 
Parkinson’s disease250. In my study, Ang II-induced cell death was not associated with 
cleaved caspase-3, at day 3. Another study, infusing the same dose of Ang II to 12 week 
old mice, also failed to find cleaved caspase-3 in the ascending aorta at day 3149. 
However, caspase-3 was detected at sites of hemorrhage during long-term infusion. 
Therefore, it appears that acute Ang II-induced death is caspase-3-independent.  Potential 
casapse-3-independent forms of cell death that may be abrogated by NR include necrosis, 
parthanatos, necroptosis, autophagic death or caspase-3-independent apoptosis251. 
Interestingly, intracellular NAD+ has been found to promote TNF-α-induced 
necroptosis252, although NR/NMN have also reliably decreased TNF-α in several 
studies238,104,253,254,255. I speculate that increasing NAD+ levels may have protected cells 
by lowering oxidative stress, reducing DNA damage, increasing DNA repair, or 
preventing ATP depletion38. Mechanisms which may have been mediated by NAD+-
dependent sirtuins. 
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4.5  NR abrogates acute Ang II-induced DNA damage  
DNA damage contributes to vascular disease9. Although Ang II-induced DNA 
damage has been studied, I am the first to directly identify aortic DNA strand breakage, 
in vivo. Using a comet assay approach, I show for the first time that Ang II causes single 
and/or double strand breaks in the aorta, and that this occurs rapidly, at day 3 of infusion. 
Importantly, this rapid destruction of DNA strands was abrogated by NR treatment.  
Several potential mechanisms may explain NR’s protective effect. Sirtuin proteins 
require NAD+ for their activity and regulate DNA repair pathways triggered in response 
to single – nucleotide excision repair and base excision repair –  and double strand breaks 
– non-homologous end joining and homologous recombination256. SIRT1 and 6 are 
particularly important. These enzymes deacetylate proteins involved in DNA repair, 
promoting their interaction, assembly, activity and stability256. Sirtuins can localize these 
proteins to sites of damage257 or promote their expression by localizing transcriptional 
regulators258. Sirtuins can also promote remodeling of the chromatin necessary for 
repair259 or delay apoptotic signaling increasing the window for repair260. In addition, 
sirtuins regulate NOX-derived ROS generation261 and anti-oxidant expression52, which 
may have directly lowered oxidative stress and secondarily DNA damage. Importantly, 
aged mice (26-28 months) treated with NMN displayed reductions in vascular superoxide 
production and ex vivo incubation of aortas with NMN upregulated superoxide dismutase 
2206. 
 Another NAD+ consumer, PARP-1, could also play a role. In response to DNA 
damage, PARP1 utilizes NAD+ to create poly(ADP)-ribose chains at damaged sites, 
forming a docking site for DNA repair proteins61. By augmenting NAD+ levels, NR may 
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have promoted DNA repair by transiently enhancing PARP-1-mediated repair. Sirtuins 
can also promote PARP activity262 and even without cleavage, NAD+ can promote 
PARP-1 activity by binding to its negative regulator, DBC-1263.  
Reports from other investigators support my findings. In muscle stem cells 
harvested from young (1 month) and old mice (22-24 months) administered NR, fewer 
cells stained positivity for the DNA damage biomarker, γ-H2AX108.  Furthermore, comet 
assay performed on these cells revealed lower levels of DNA damage with NR treatment. 
NR administration also lowered the number of γ-H2AX positive hepatocytes in a 
hepatocyte carcinoma model driven by NAD+ synthesis deficits and DNA damage264. 
Moreover, liver cells of mice exposed to γ-radiation have lower levels of 8-oxo-dG and 
fewer AP sites when mice are treated with nicotinamide265. In vitro, NAD+ and its 
precursors have protected PBMCs266, PC12 cells250, and cortical neurons249 from DNA 
damage. 
Many of the aforementioned studies and studies involving Ang II-infusion, have 
detected breakage of DNA indirectly, by measuring levels of γ-H2AX176. Early in the 
DNA damage response, histone H2AX is phosphorylated, forming γ-H2AX and 
recruiting repair proteins to sites of damage267. However, H2AX has been shown to be 
phosphorylated during cell cycle progression268, which may confound its use as a DNA 
damage biomarker. Therefore, an increase in γ-H2AX may be due to mitotic arrest or 
increased proliferation, which can be induced by Ang II269,270. γ-H2AX can also be seen 
in senescent cells, which has been argued to reflect persistent DNA damage foci271 and/or 
sites of chromatin remodeling that are not associated with DNA damage272. Direct 
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assessment of DNA damage with the comet assay overcomes these limitations caused by 
indirect measures. 
In summary, my work demonstrates, for the first time, that vascular cells within 
the aorta are susceptible to early destruction of DNA – with DNA breaks in both ECs and 
VSMCs. Oral administration of NR can abrogate this. 
 
4.6  NR abrogates sustained Ang II-induced DNA oxidative damage 
 
I found that after 28 days of Ang II infusion, oxidation of guanine nucleobases in 
vascular cells of the thoracic aorta was also lower in mice fed NR. Interestingly, DNA 
damage at day three, expressed as tail moment, and at day 28, expressed as the 
percentage of 8-oxo-dG-positive cells, was greater in ECs compared to VSMCs. This 
indicates that aortic ECs are more susceptible to Ang II-induced DNA damage than 
VSMCs. This differential pattern was also seen for the cell death response in the aorta 
after three days of Ang II.  
 
4.7  NR confers region-specific protection from Ang II-induced aortic 
thickening 
Infusion of Ang II for 28 days thickens the aorta, independent of blood pressure 
and via actions on the AT1 receptor128. In the ascending aorta, thickening occurs due to 
hyperplasia, while cell hypertrophy is responsible in other aortic regions128. In agreement 
with other studies, I observed thickening in the ascending, thoracic and suprarenal 
regions of the aorta128. NR did not impact thickening in the ascending and thoracic 
region. However, thickening was blunted at the suprarenal region. This region-specific 
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difference in NR’s effect is interesting. It may be due to the embryological origins of 
VSMCs, which differ between the ascending, thoracic and abdominal aorta273. These 
VSMCs originate from the neural crest, somite, and splanchnic mesoderm, respectively. 
Interestingly, VSMCs isolated from these sites have exhibited differential growth and 
transcriptional responses, raising the possibility that they may respond differently to 
NAD+ precursors273,274. In addition, CD38 expression varies markedly between vascular 
regions99. Therefore, it is possible that the aorta exhibits regional variations in the 
expression of enzymes involved in NAD+ homeostasis, and thus responses to precursors. 
 
4.8  NR prevents sustained Ang II-induced VCAM-1 expression 
The role of inflammation in cardiovascular diseases, and particularly 
atherosclerosis, has been widely studied. The cell adhesion molecule VCAM-1 allows for 
the adhesion of monocytes to the vessel lumen160. Monocytes can subsequently enter the 
vessel wall (transmigration), differentiate into macrophages and phagocytose lipid, 
becoming foams cell and forming an atherosclerotic plaque160. Therefore, reducing the 
expression of VCAM-1 may be an important step towards preventing atherosclerotic 
plaque formation. In agreement with other studies, I found increased VCAM-1 
expression after Ang II infusion, indicative of chronic EC dysfunction and a 
proinflammatory  vascular state183. Importantly, this was suppressed by NR 
administration.  
Transcription of VCAM-1 is mediated by NF-κB and is responsible for its 
upregulation by Ang II186. SIRT1 suppresses NF-κB activity by deacetylating its p65 
subunit, a process which is prevented during NAD+ depletion275. Therefore, NR may 
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have augmented NAD+ levels, fueling SIRT1 mediated NF-κB suppression. Beyond 
directly boosting NAD+, reductions in oxidative stress and DNA damage could play a 
role, because PARP-1276 and 8-oxo-dG170 are linked to NF-κB-driven transcription. 
Importantly, I found that NR lowered the number of p16INK4A-positive ECs, suggesting 
fewer senescent cells. This may also be responsible as subsets of senescent ECs exhibit 
prolonged VCAM-1 expression277.   
In agreement with our results, NR abrogated a HFD-induced increase in liver 
VCAM-1 transcript abundance. However, in contrast, NMN did not lower VCAM-1 
expression in a model of intracerebral hemorrhage. NMN was injected 30 minutes after 
hemorrhage and inflammation was assessed after 3 days, while we assessed VCAM-1 
after long-term NR treatment and Ang II infusion. Differences in models, cell types, 
NAD+ precursors and route of administration may be responsible. NAD+ precursors have 
also mitigated inflammation in aging108, muscle damage108 and metabolic disease 
models104,106,253,255.   
4.9  NR attenuates chronic Ang II-induced p16INK4A expression  
During aging, heavily damaged cells can adopt a senescent phenotype. This is 
characterized by permanent cell cycle arrest and the secretion of pro-inflammatory 
cytokines. Clearance of these cells has improved health278,279 and lifespan280 in animal 
models, including vascular endpoints such as carotid artery vascular reactivity281. 
p16INK4A is a commonly used biomarker of senescence, and prevents cell cycle 
progression by suppressing the expression of S-phase genes179.  I found that NR 
abrogated EC and VSMC p16INK4A expression induced by Ang II infusion. 
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The observed reduction in senescence may be due to NR-mediated preservation of 
genomic integrity. This is because prolonged or severe DNA damage may trigger 
senescence as a means to prevent the propagation of mutated DNA, which could give rise 
to dysfunctional proteins and cells9. In addition, NAD+-driven sirtuins can prevent 
senescence by negatively regulating senescence-inducing proteins including p53, 
forkhead box protein O1, Notch intracellular domain and plasminogen activator 
inhibitior-1282. 
Similar to my results, Ang II-induced VSMC senescence was found to be reduced 
in mice administered the NAD+-boosting compound PNU-282987176. NR has also 
ameliorated senescence in muscle stem cells from mdx-muscular-dystrophy mice and 
protects neural and melanocyte stem cells from senescence108. Furthermore, we124 and 
others283 have found cultured cells supplemented with NAD+ precursors are protected 
from H2O2-induced senescence.  
One limitation of my assessment of senescence is the sole use of p16INK4A. p16 
upregulation is known to induce cell cycle arrest, but mutations in downstream proteins 
responsible for executing senescence can prevent this179. Moreover, transient p16 
upregulation has been observed during wound healing and tissue repair284. This may 
reflect the clearance of senescent cells, or a transient increase in p16 that is not associated 
with senescence. Using two biomarkers, such as p21 and senescence associated β-
galactosidase (β-Gal), may strengthen findings. Nevertheless, Ang II has been well 
established to induce vascular cell senescence in the aorta, including in our previous 
study110 and that of others54. Thus it can be more confidently concluded that cells positive 
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for p16INK4A were senescent. As well, we have previously demonstrated that NR lowers 
β-Gal positivity in ECs and VSMCs exposed to H2O2124.  
My results indicate that an abrupt increase in Ang II, followed by sustained 
delivery in middle-aged mice, causes vascular cell senescence. This is a pathological state 
that can be prevented by NR supplementation.  
 
4.10  Limitations 
There are limitations to my study. This study was only performed in male mice.  
Whether female mice are also susceptible to acute Ang II-induced cell death and DNA 
damage, and whether these can be abrogated by NR warrants specific study. In addition, 
NAD+ levels within the aorta were not measured so I cannot be certain that NR 
augmented NAD+ levels in ECs and VSMCs. Regarding my assessment of cell death, 
EthD-III-positive cells could include cells with transient but repairable cell membrane 
damage. In addition, the sole use of p16INK4A to assess senescence is a limitation. This 
could be overcome by using additional markers for senescence, as noted in section 4.9. 
 
4.11  Future directions 
Ang II infusion has been used experimentally for decades to induce vascular 
pathology. A novel and important finding of this thesis is the extent of EC death/injury 
following acute Ang II infusion. Future work should thoroughly investigate the mode of 
Ang II-induced cell death, by blocking specific death subroutines through genetic or 
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chemical means. Furthermore, the downstream impact of these dead cells on vascular 
homeostasis and their incidence during natural aging would be of interest.  
The use of NR in other contexts of vascular injury, such as atherosclerosis and 
plaque rupture would also be interesting. In addition, comprehensive evaluation of NAD+ 
consuming/synthesizing enzyme expression throughout the aorta and their change during 
age and Ang II should be studied. Moreover, studies of oral NR digestion/absorption are 
needed to inform drug administration protocols. Whether protection from Ang II-induced 
damage can be conferred without NR pre-treatment should also be investigated.  
Translationally, administration of NR in vascular diseases associated with 
ROS/DNA damage/inflammation/senescence should be considered. Directly assessing 
DNA effects would be challenging, but may be possible in patients undergoing surgical 
procedures. For instance, comet assay has been performed on VSMCs taken from 
atherosclerotic plaques from patients undergoing endarterectomy173. Less invasively, 
others have acutely infused Ang II to humans and used plasma oxidation markers to 
assess efficacy of a therapeutic intervention285. Hypertensive emergencies are associated 
with endothelial cell damage201, ROS201 and inflamation286. During these events, patients 
visit the emergency room and receive medication to lower blood pressure. An intriguing 
trial would involve acute administration of NR, and collection of blood to assess 
oxidation, endothelial cell damage (vWF) and inflammation (soluble VCAM-1, C-
reactive protein).  
Pre-clinical studies of NAD+ precursors have demonstrated potential therapeutic 
benefits. The results of this thesis demonstrate that vascular diseases and vascular 
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endpoints should be considered when designing clinical trials to evaluate the benefits of 
supplementation with NR and other NAD+ precursors. 
 
4.12  Conclusion 
In conclusion, I have found that NR protected the aorta of middle-aged mice from 
oxidative stress-associated pathology induced by Ang II infusion. These results support 
my overriding hypothesis. Specifically, NR abrogated acute early cell death and DNA 
damage induced by infusion of Ang II. As well, improvements in genomic integrity were 
evident following sustained Ang II infusion. This was associated with reduced 
proinflammatory signaling and reduced senescence in ECs and VSMCs. Collectively, 
these results suggest that NR has the capacity to protect the vasculature from acute and 
chronic vascular insults. 
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6  APPENDICES 
Appendix A: Animal Use Protocol  
	
AUP Number: 2010-244 
PI Name: Pickering, Geoffrey 
AUP Title: Smooth Muscle Cells and Vascular Disease 
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2010-244 has been approved. 
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through the ACVS 
office. 
Health certificates will be required. 
REQUIREMENTS/COMMENTS 
Please ensure that individual(s) performing procedures on live animals, as described in this 
protocol, are familiar with the contents of this document. 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with institutional 
safety standards and have received all necessary approvals. Please consult directly with your 
institutional safety officers. 
Submitted by: Thompson, Sharla H  
on behalf of the Animal Use Subcommittee  
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